University of South Florida

Scholar Commons
Graduate Theses and Dissertations

Graduate School

September 2015

Function of Long Noncoding RNAs in Breast
Cancer
Edward J. Richards
University of South Florida, erichards@mail.usf.edu

Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the Cell Biology Commons, and the Molecular Biology Commons
Scholar Commons Citation
Richards, Edward J., "Function of Long Noncoding RNAs in Breast Cancer" (2015). Graduate Theses and Dissertations.
http://scholarcommons.usf.edu/etd/5767

This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.

Function of Long Noncoding RNAs in Breast Cancer

by

Edward Richards

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
Department of Cell Biology, Microbiology, and Molecular Biology
College of Arts and Sciences
University of South Florida

Major Professor: Jin Q. Cheng, M.D., Ph.D.
Ed Seto, Ph.D.
Jerry Wu, Ph.D.
Domenico Coppola, M.D.
Conor Lynch, Ph.D.

Date of Approval:
June 15, 2015

Keywords: TGFβ, epithelial to mesenchymal transition, metastasis
Copyright © 2015, Edward Richards

DEDICATION

This dissertation is written with dedication to my family and friends.

ACKNOWLEDGMENTS

Foremost, I would like to acknowledge my mentor Dr. Jin Q. Cheng for allowing
me to pursue this work. I appreciate the freedom and your confidence to study the
function of lncRNAs at a time when the field was young and still emerging. Under your
supervision, I have learned a great deal not only about the science, but also being a
professional in the community. This dissertation is a direct reflection of your positive
mentorship and hard work. I very much appreciate your help and guidance.
In addition, I would like to thank my internal and external committee members
that have contributed intellectually and motivationally to this work; Dr. Domenico
Coppola, Dr. Jerry Wu, Dr. Conor Lynch, Dr. Ed Seto, and Dr. Xiao-Fan Wang. In
addition, I would like to acknowledge The Cancer Biology Ph.D. Program for their
acceptance into the program and for the strong education I have received over the past
years. In particular I would like to thank program director, Dr. Ken Wright, and program
coordinator, Cathy Gaffney.

ii

TABLE OF CONTENTS
List of Tables ................................................................................................................... v
List of Figures................................................................................................................. vi
Abstract .......................................................................................................................... ix
Chapter 1: Background.................................................................................................... 1
Breast Cancer....................................................................................................... 1
Types of Breast Lesions and Carcinomas.................................................. 2
Hereditary Breast Cancer........................................................................... 4
Molecular Pathological Subtypes of Breast Cancer. .................................. 5
Human genome and long noncoding RNAs (lncRNAs). ....................................... 7
Genomic landscape. .................................................................................. 7
Characteristics of lncRNA. ......................................................................... 8
Conservation of lncRNA........................................................................... 10
Mechanisms of lncRNA Function........................................................................ 12
Epigenetic and chromatin modification..................................................... 12
Sponge for miRNAs. ................................................................................ 14
Messenger RNA Processing and Protein Translation. ............................. 15
Enhancers and transcriptional activation.................................................. 16
Decoy for protein binding. ........................................................................ 17
LncRNAs in Cancer and Malignancy .................................................................. 18
HOTAIR. .................................................................................................. 18
XIST. ........................................................................................................ 19
MEG3....................................................................................................... 21
ANRIL. ..................................................................................................... 22
Emerging lncRNAs in cancer. .................................................................. 22
TGFβ Signaling Pathway .................................................................................... 23
TGFβ Signaling Pathway and Ligands. .................................................... 23
TGFβ Signaling Pathway Receptors. ....................................................... 24
TGFβ Signaling Pathway SMAD Proteins. ............................................... 25
TGFβ-associated phenotypes and genes. .......................................................... 28
Epithelial to Mesenchymal Transition (EMT)............................................ 28
Changes in Gene Expression Associated with EMT. ............................... 29
Cancer Stem Cells (CSCs). ..................................................................... 32
Breast Cancer Stem Cells (BCSCs)......................................................... 33

i

Chapter 2: Identification of lncRNAs regulated by TFGβ in mouse mammary
epithelia and strategy to identify human orthologs. .................................................. 36
Introduction ......................................................................................................... 36
Results................................................................................................................ 39
Profile of lncRNA expression in TGFβ-induced EMT in NMuMG
cells .................................................................................................... 39
Strategy used to discover conserved human ortholog lncRNAs. ............. 42
Test for expression of predicted human ortholog transcript. .................... 44
Human AK578 is over-expressed in human breast cancer patient. ......... 47
Methods.............................................................................................................. 49
LncRNA Microarray.................................................................................. 49
RNA isolation and RT- and semi- qPCR polymerase chain
reaction............................................................................................... 50
Chapter 3: lncRNA-HIT mediates TGFβ-induced EMT in mammary epithelia
and associates with metastasis and poorer overall patient survival ......................... 54
Introduction ......................................................................................................... 54
Results................................................................................................................ 55
LncRNA-HIT mediates TGFβ-induced invasion, migration, and
EMT in NMuMG cell. ................................................................................ 55
LncRNA-HIT mediates TGFβ induced motility and EMT. ......................... 56
Ectopic expression lncRNA-HIT increases cell motility and EMT............. 57
LncRNA-HIT is up-regulated in 4T1 cells and its depletion
inhibits cell migration, invasion, lung metastasis and tumor
growth................................................................................................. 59
Identification of E-cadherin as a major target of lncRNA-HIT................... 61
LncRNA-HIT is conserved across several species. ................................. 61
LncRNA-HIT is elevated in several human breast cancer cell
lines and knockdown reduces migration and invasion. ....................... 63
Depletion of lncRNA-HIT decreases primary tumor growth and
metastasis in vivo. .............................................................................. 65
LncRNA-HIT regulates 5-prime distal HOXA genes including
HOXA13. ............................................................................................ 67
HOXA13 is important in driving breast cancer migration and
invasion. ............................................................................................. 68
LncRNA-HIT is elevated in patient invasive ductal carcinoma,
high grade tumor, positive lymph node, and associates with
poorer patient survival. ....................................................................... 69
Discussion .......................................................................................................... 72
Methods.............................................................................................................. 74
Plasmids and siRNAs............................................................................... 74
Affymetrix Gene Expression Array ........................................................... 74
Invasion and migration assays................................................................. 74
Cell Lines, treatment, and tumor specimens. ........................................... 75
Immunofluorescence, immunoblotting, and antibodies. ........................... 75

ii

Soft agar colony formation assay............................................................. 76
Luciferase reporter assay......................................................................... 76
Mouse orthotopic injection. ...................................................................... 77
Locked nucleic acid in situ hybridization of formalin-fixed,
paraffin-embedded tissue microarray (LNA-TMA-ISH). ...................... 77
Chapter 4: WDFY3-AS2 promotes breast cancer EMT, metastasis, and
associates with poorer patient survival and triple-negative breast cancer................ 79
Introduction ......................................................................................................... 79
Results................................................................................................................ 80
BB049 and human ortholog WDFY3-AS2 are regulated by TGFβ
in mammary epithelia.......................................................................... 80
WDFY3-AS2 is elevated in human cancer and associates lymph
node metastasis, high grade tumor, triple-negative subtype,
and poorer patient survival. ................................................................ 82
WDFY3-AS2 regulates TGFβ-induced EMT in HMEC. ............................ 82
WDFY3-AS2 regulates migration, invasion, proliferation, and
cell cycle. ............................................................................................ 84
Knockdown of WDFY3-AS2 inhibits primary tumor growth and
metastasis in vivo. .............................................................................. 86
WDFY3-AS2 regulates protein coding gene WDFY3 in ‘cis’ and
STAT3 in ‘trans’. ................................................................................. 89
WDFY3-AS2 and WDFY3 are co-expressed and elevated WDFY3
is also a predictor of poorer patient survival. ...................................... 91
WDFY3-AS2 binds to hnRNP-R to regulate WDFY3 and STAT3. ........... 93
Discussion .......................................................................................................... 96
Methods.............................................................................................................. 99
Invasion and migration assays................................................................. 99
Cell Lines, treatment, and tumor specimens. ........................................... 99
Locked nucleic acid in situ hybridization of formalin-fixed,
paraffin-embedded tissue microarray (LNA-TMA-ISH). .................... 100
Mouse orthotopic injection. .................................................................... 100
Affymetrix Gene Expression Array. ........................................................ 100
Immunofluorescence, immunoblotting, and antibodies. ........................ 101
Plasmids and siRNAs............................................................................. 101
RNA immunoprecipitation (RIP) assay................................................... 102
Chapter 5: LncRNA TIL involved in breast cancer EMT, metastasis, and cancer cell
stemness through regulation of NF90/C-MYC........................................................ 103
Introduction ....................................................................................................... 103
Results.............................................................................................................. 104
TGFβ-regulated AK060 and human ortholog TIL. .................................. 104
TIL is elevated in human breast cancer and associates with late
stage tumor and triple-negative breast cancer.................................. 105
TIL regulates migration, invasion, and has elevated expression in
BCSCs. ............................................................................................. 107

iii

TIL post-transcriptionally regulates C-MYC............................................ 109
TIL binds to NF90................................................................................... 111
C-MYC binds to NF90. ........................................................................... 113
TGFβ induces TIL-dependent shuttling NF90/C-MYC to cytosol. .......... 115
TIL enhances AKT phosphorylation of NF90 at Ser647. ........................ 116
Discussion ........................................................................................................ 118
Methods............................................................................................................ 121
RNA immunoprecipitation (RIP) assay................................................... 121
Locked nucleic acid in situ hybridization of formalin-fixed,
paraffin-embedded tissue microarray (LNA-TMA-ISH). .................... 122
Immunofluorescence, immunoblotting, and antibodies. ........................ 122
Plasmids and siRNAs............................................................................. 122
BCSCs sorting by flow for RT-qPCR...................................................... 123
Dual reporter luciferase assay. .............................................................. 123
Chapter 6: Conclusions and Implications .................................................................... 124
References Cited......................................................................................................... 129
Appendix ..................................................................................................................... 141

iv

LIST OF TABLES
Table 1. Species of RNA in the human genome............................................................ 9
Table 2. The biological mechanisms of lncRNA function............................................. 14
Table 3. Top lncRNAs up-regulated in TGFβ-induced EMT in NMuMG ...................... 52
Table 4. Top lncRNAs down-regulated in TGFβ-induced EMT in NMuMG ................. 53

v

LIST OF FIGURES
Figure 1.

The characteristic features and orientation of lncRNAs. ............................. 10

Figure 2.

LncRNA can function in “cis” or in “trans”. .................................................. 13

Figure 3.

The TGFβ signaling pathway and associated molecules............................ 26

Figure 4.

The SMAD family of proteins. ..................................................................... 28

Figure 5.

The epithelial to mesenchymal transition (EMT) in breast cancer. ............. 30

Figure 6.

EMT-associated markers and phenotypes. ................................................ 32

Figure 7.

The “Stochastic” and “Hierarchal” models of cancer stems cells. ............... 35

Figure 8.

LncRNA expression profile of TGFβ-induced EMT in NMuMG cells........... 40

Figure 9.

Verification of TGFβ-regulated lncRNAs..................................................... 41

Figure 10. Dysregulated mRNAs in TGFβ-induced EMT. ............................................ 45
Figure 11. Schematic representation and workflow for identifying conserved
human orthologs. ........................................................................................ 46
Figure 12. Ortholog lncRNAs are also regulated by TGFβ and overexpressed
in breast cancer cell lines. .......................................................................... 48
Figure 13. Mouse AK578 has human ortholog transcript and is up-regulated
in patient breast tumor. ............................................................................... 51
Figure 14. LncRNA-HIT locates in Hoxa gene cluster and is induced by
TGFβ. ......................................................................................................... 56
Figure 15. LncRNA-HIT mediates TGFβ-induced cell migration, invasion and
EMT ............................................................................................................ 58
Figure 16. Over-expression of lncRNA-HIT promotes migration, invasion and
disrupts tight junction. ................................................................................. 59

vi

Figure 17. LncRNA-HIT is elevated in highly metastatic 4T1 cells and its
knockdown results in significant reduction of cell migration,
invasion, and metastasis. ........................................................................... 62
Figure 18. E-cadherin is a target of lncRNA-HIT.......................................................... 63
Figure 19. LncRNA-HIT is conserved in across several species and human
ESTs have been reported........................................................................... 64
Figure 20. Human lncRNA-HIT is over-expressed in several breast cancer
cells lines and depletion of results in reduced migration and
invasion. ..................................................................................................... 65
Figure 21. NSG mouse orthotopic xenograft model of control versus depleted
lncRNA-HIT. ............................................................................................... 67
Figure 22

LncRNA-HIT knockdown results in decreased mRNA expression
neighboring genes and HOXA13 protein. ................................................... 68

Figure 23. HOXA13 depletion changes cell morphology and results in
decreased migration and invasion. ............................................................. 70
Figure 24. Elevated levels of lncRNA-HIT associates with invasive breast
cancer in human, late grade tumor, positive lymph node, and
poorer overall patient survival..................................................................... 71
Figure 25. BB049 and human ortholog WDFY3-AS2 are regulated by TFGβ
in mammary epithelia.................................................................................. 81
Figure 26. WDFY3-AS2 is over-expressed in human patient tumor,
metastasis, and is associated with poor patient survival and
triple-negative breast cancer. ..................................................................... 83
Figure 27. Knockdown of WDFY3-AS2 inhibits TGFβ induced EMT. .......................... 84
Figure 28. Knockdown of WDFY3-AS2 inhibits TGFβ-induced migration and
invasion. ..................................................................................................... 85
Figure 29. Knockdown of WDFY3-AS2 in MD-AMB-231 reduces migration,
invasion, proliferation, and results in G1 accumulation............................... 87
Figure 30. Ectopic expression of WDFY3-AS2 increases invasion,
proliferation, and G2-S population. ............................................................. 88
Figure 31. Orthotopic mouse model demonstrates that knockdown of
WDFY3-AS2 significantly inhibits tumor growth and metastasis................. 90

vii

Figure 32. WDFY3-AS2 regulates protein coding gene WDFY3 in “cis” and
STAT3 in “trans” mechanism. ..................................................................... 91
Figure 33. WDFY3-AS2 and WDFY3 are co-expressed in patient and
elevated WDFY3 predicts poorer patient survival. ...................................... 94
Figure 34. Tumor lysates and staining in mouse orthotopic xenograft model. ............. 95
Figure 35. WDFY3-AS2 binds to hnRNP-R. ................................................................ 97
Figure 36. AK060 has a conserved TGFβ-regulated lncRNA ortholog, TIL. .............. 105
Figure 37. TIL is elevated in breast cancer cell line and patient tumor RNA.............. 106
Figure 38. TIL is progressively up-regulated with advanced disease and
associates with late stage tumor, positive lymph node, and
triple-negative breast cancer. ................................................................... 108
Figure 39. TIL regulates migration, invasion, and has higher expression in
BCSCs. ..................................................................................................... 110
Figure 40. TIL regulates C-MYC protein expression but has no effect on
mRNA expression..................................................................................... 112
Figure 41. TIL binds NF90. ........................................................................................ 114
Figure 42. NF90 binds C-MYC 3-prime UTR. ............................................................ 116
Figure 43. TGFβ enhances TIL-dependent NF90 and C-MYC mRNA shuttling
to cytosol. ................................................................................................. 117
Figure 44. TIL promotes phosphorylation of NF90 at Ser-647. .................................. 119
Figure 45. A model proposed by which TIL regulates C-MYC through NF90 ............ 121

viii

ABSTRACT

Breast cancer is a disease that will be diagnosed in about 1 in 10 women
throughout their lifetime. The majority of breast cancers are originated from the
epithelial cells of the mammary ducts, and this occurrence can be due to several factors
including hereditary and acquired mutation. There are several major breast cancer
subtypes, including estrogen receptor-α (ERα)-positive, HER2-enriched and triplenegative (TNBC). Patients diagnosed with ER+ tumors are generally treated with
estrogen blockers (e.g., tamoxifen, letrozole and fulvestrant). Patients with HER2+
tumors are commonly administered with drugs that block HER2 signaling (e.g.,
trastuzumab) or inhibit HER2’s tyrosine kinase activity (e.g., lapatinib). For patients with
TNBC, chemotherapies such as taxanes and anthracyclines are standard of care
therapies.
However, for each breast cancer subtype, a significant number of patients
develop resistance to these therapies and eventually die from metastasis, a process
which accounts for ~90% of breast cancer mortality. Currently, metastatic breast cancer
is incurable, and the short median survival of 3 years for patients with metastatic breast
cancer has not significantly changed in over 20 years. Therefore identification of new
molecules that are involved in breast cancer metastasis and development of more
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precisely targeted therapeutic strategies are urgently needed to improve the clinical
outcome for this disease.
The transforming growth factor pathway beta (TGFβ) pathway has been show to
play a key role in metastasis through induction of epithelial-mesenchymal transition
(EMT), cell migration and invasion. Over more than a decade, this pathway has been
studied across several cancers and it is now better established that it has contextdependent tumor suppressive and oncogenic qualities. In the early stages of breast
cancer, TGFβ pathway is a suppressor of benign and early stage tumor growth.
However, as disease progresses and corresponding levels of TGFβ ligands become
elevated, a “switch” will take place and promote oncogenic phenotypes like EMT and
cancer cell stemness which drive metastasis.
Long noncoding RNAs (lncRNAs) are an emerging subclass of RNA molecules in
cancer biology. LncRNAs are >200nt and can influence target gene expression locally in
“cis”, or along a distant chromosome in “trans”, through various mechanisms and
interactions with other biological molecules. The contribution of TGFβ-regulated
lncRNAs to associated phenotypes like EMT and cancer cell stemness has not been
very well studied. The aim of this doctoral dissertation is to address the functional and
mechanistic roles of lncRNAs in these processes.

Using a well-established TGFβ-

induced EMT model (e.g., mouse mammary epithelial cell NMuMG treated with TGFβ),
we have identified 3 conserved lncRNAs (lncRNA-HIT, WDFY3-AS2 and TIL) that are
significantly upregulated upon TGFβ-induced EMT. They all mediate TGFβ-induced
EMT, cell migration and invasion.

Overexpression of these lncRNAs is frequently

detected during the breast cancer progression and is associated with high grade and
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late stage of breast cancer as well as metastatic lesion. We have also demonstrated
that lncRNA-HIT positively regulates HOXA13 through “cis” mechanism and that
WDFY3-AS2 induces WDFY3 and STAT3 expression at mRNA level by direct
interaction with hnRNP-R. Interestingly, TIL stimulates C-MYC protein but not mRNA
expression by promoting Akt phosphorylation of NF90 leading to its translation from the
nucleus to cytosol where NF90 binds to C-MYC mRNA and enhances C-MYC
translation. Importantly, we have shown that knockdown of lncRNA-HIT and WDFY3AS2 significantly reduces breast cancer growth and lung metastasis in orthotopic breast
cancer model. These findings indicate that these TGFβ-induced lncRNAs play critical
role in EMT, metastasis, and are relevant in human patient tumors. Therefore, it is
important to consider utilizing these molecules for clinical applications like diagnosis,
monitoring recurrence, predicting a response to therapy, and even as a direct target for
therapeutic intervention.
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CHAPTER 1
Background

Breast Cancer. In 2014, there will be an estimated 230,000 new cases of breast
cancer diagnoses and 40,000 deaths resulting from the disease [1]. Breast cancer can
arise in various anatomic locations within the breast. Commonly, cancer will arise in the
ducts towards to front of the breast, and less frequently in the lobules that locate closer
to the chest wall and the other areas in between. Upon diagnosis breast cancer staging
will occur, which accounts for size of primary mass, degree of invasiveness, and
presence of metastasis in lymph nodes or other parts of the body. Patients diagnosed in
early stages (e.g., stage I or stage II) and who present no local dissemination of cells in
lymph node have a very good prognosis with 5-year survival greater than 90%.
However, if diagnosed at later stages, 5-year survival drops significantly to 72% at stage
III and 22% presenting at stage IV. For this reason, early diagnosis and prevention are
critical for improving patient survival.
Several factors have been linked to increasing an individuals risk for developing
breast cancer throughout their lifetime including genetic predisposition, atypical
menstruation patterns, obesity, high fat diet, and lacking exercise. There is no way to
predict who will develop breast cancer, however it is important to be aware of familial
history, have regular mammogram screening, and maintain healthy lifestyle to best
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prevent disease occurrence. There are 3 standard therapies used to treat breast cancer,
surgery, radiation, and chemotherapy [2]. For most early stage cancers, surgical
lumpectomy is sufficient treatment which removes a small mass and some normal
surrounding tissue to clear borders of any residual cancer cells. If the disease is more
advanced, surgery can become more invasive and favor partial or modified radical
mastectomy where larger portions or complete breast is removed. External or internal
radiation treatments (high energy x-rays) are usually given post-surgery to locally clear
the area of any remaining cancer cells. Several chemotherapeutic drugs are now
approved for treatment of breast cancer in form of alkylating agents, anthracyclines,
platinum drugs and taxanes [2]. The chemotherapeutic treatment chosen will also likely
take into account pathological characteristics of tumor as more targeted therapies
become available.

Types of Breast Lesions and Carcinomas. Breast cancers originate in the
epithelial compartment once increased cellular proliferation and abnormal cellular
architecture becomes evident. There is typical progression from normal to precancerous lesion to carcinoma that initially presents itself in the form of a hyperplasia.
The term of hyperplasia refers increased number of proliferative cells, and is
accompanied by an increase in cell size referred to as hypertrophy. A hyperplasia is a
benign lesion, but can develop into a neoplasia or pre-cancerous lesion once genetic
abnormalities persist and the cell becomes unresponsive to cues that halt cell cycle and
resist apoptosis. The aggressiveness of the lesion can be evaluated by the tumor grade.
These features are clinically and pathologically relevant as to how a pre-cancerous
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lesion is diagnosed and provide information as to rate of recurrence and how
aggressive the carcinoma may become [3].
Ductal carcinoma in situ (DCIS) is the most common form of breast tumor
associated with development of invasive breast cancer. DCIS is considered stage 0
breast cancer, as this refers to the fact that the mass has yet to become invasive and
push past the boundaries of the basement membrane remaining confined to the duct [4].
Depending on how the mass is formed and patterned DCIS can be subdivided into
papillary, with finger-like projections, crib-form in which there are gaps between cells, or
solid in which gaps are completely filled inside and blocking the duct [5]. Lobular
carcinoma in situ (LCIS) anatomically presents itself in the lobular compartment of the
breast. The lobular component of the breast is the milk producing area located beyond
the ducts and closer to the chest wall. LCIS, like DCIS, is confined to the lobules and
has not invaded or spread to any surrounding tissues. LCIS is less frequently diagnosed
however, as it is hard to view via standard mammogram and no symptoms are present
during this stage of pre-cancerous lesion.
Invasive ductal carcinoma (IDC) is the most common type of breast cancer
encompassing about 80% of all diagnoses. Advanced DCIS will form IDC once the
mass has spread beyond the boundaries of the basement membrane and has infiltrated
the surrounding tissue of the breast. Early detection of IDC is critical in that once the
tumor protrudes through the duct wall metastasis to the lymph node or other parts of the
body can rapidly occur. The majority of cases of women at diagnosis are postmenopausal and close above the age of 55. Invasive lobular carcinomas (ILCs) are
much less commonly diagnosed and account for about 10% of all new breast cancer
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cases. ILC results once LCIS has spread into the surrounding tissues and areas of the
breast surrounding the lobules. It is common for women to be diagnosed with ILC at a
later age than IDC and it has also been suggested that hormone replacement therapy
can trigger development of this disease.

Hereditary Breast Cancer. Hereditary breast cancer refers to inherited
mutations in particular genes that put women at higher risk for developing breast cancer
throughout their lifetime and at an earlier age. The most common type of hereditary
breast cancer is inheriting mutations in a single copy of either BRCA1 or BRCA2 genes
[6]. The mutations in BRCA1 and BRCA2 are referred to as single nucleotide
polymorphisms (SNPs), which are naturally occurring variations within the DNA of the
genome that differs by one nucleotide within a population. SNPs that locate within the
coding region or open reading frame of a protein have the ability to alter amino acid
sequence and protein secondary structure which can alter normal gene function and
protein stability. BRCA1 and BRCA2 are referred to as tumor suppressor genes,
responsible for DNA damage repair and maintaining chromosomal stability and integrity
[7]. Patients who inherit a mutation within one of these two genes will have deficient
DNA damage repair response and accumulate genetic mutations at a higher rate than
those with normal BRCA status. These associated mutations account for the majority of
hereditary breast cancer, and about 10% of all new case of diagnosed breast cancers.
There are several other genes that have also been implicated in familial and
hereditary breast cancer, however no other gene mutations have showed comparable
penetrance rate as that of BRCA1 and BRCA2. Many of the other genes that have

4

shown susceptibility to breast cancer development are also involved in the DNA
damage repair pathway, which include ATM, CHEK2, PALB, RAD50, and MRE11 [8-12].
These genes all play critical roles in DNA damage repair, and can form complex
with each other to elicit a robust functional response. Therefore, it is possible that a
mutation rendering one of these genes non-functional can result in faulty repair due to
dominant-negative effect. Other classical tumor suppressor genes have also been
implicated as contributing to hereditary breast cancer, including p53 and PTEN genes
[13, 14]. P53 is the most commonly mutated gene in all of human cancer (~50%), and is
critical for cell cycle arrest and initiation of apoptosis. PTEN tumor suppressor is the
major negative regulator of PI3K/AKT signaling pathway. Loss of PTEN expression and
function can occur through various mechanisms, resulting in increased cell survival and
proliferation.

Molecular Pathological Subtypes of Breast Cancer. Luminal A and luminal B
are the most common types of breast cancer accounting for 40% and 20% of all
diagnosed cases, respectively [15]. Luminal breast cancers are named such in that they
originate from the epithelial layer of the luminal lining in the mammary duct. Luminal A
breast cancer is defined molecularly as estrogen receptor-positive (ER+) and/or
progesterone receptor PR-positive (PR+), HER2/neu receptor-negative (HER2-), and a
low percentage of p53 mutation (<15%). Luminal A has the most positive prognosis of
all subtypes of the breast cancers, a low recurrence rate, and targeted hormone
therapies based on ER-positive status [16, 17].
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Luminal B cancers are classified same as luminal A in ER+ and/or PR+, however
are also HER2+ and have a greater Ki-67 index which is a marker of cellular
proliferation. The prognosis for luminal B tumors is poorer than those diagnosed for
luminal A. Several factors such as up-regulation of the HER2 receptor, frequent p53
mutations, poorly differentiated tumor, and larger tumor size all contribute to poorer
survival rates. Although, given ER+ and HER2+ status, targeted and hormonal
therapies do exist for luminal B cancers [18].
HER2/neu subtype refers to a breast cancer in which this is the only the HER2
receptor up-regulated, and not ER or PR. HER2/neu subtype accounts for the least
amount of cases diagnosed amongst all the subtypes at only about 10-15% of all cases.
HER2/neu tumors tend to be diagnosed at younger age, have more frequent recurrence,
higher rates of metastasis, and poorer prognosis primarily due to accompanying large
percentage of p53 mutations [19]. A monoclonal antibody targeted therapy called
trastuzumab (Herceptin) is commonly used to treat HER2+ tumors [20].
Triple-negative breast cancer (TNBC) subtypes are negative for all three
receptors (e.g., ER, PR and HER2) and have by far the poorest prognosis of all breast
cancers. The 5-year survival for early stage diagnosis of triple negative breast cancer is
only 77% [21]. TNBC is more basal-like as compared to other subtypes having features
reminiscent of the cells surrounding the mammary duct and not in the lumen. These
tumors tend to be very aggressive with high rates of metastasis, and due to the negative
status of all receptors there are limited treatment options outside of surgery, radiation,
and standard chemotherapy [22].
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Recent advances in technology like whole genome sequencing, microarray, RNA
sequencing, and proteomic analysis have been valuable tools in continually redefining
the molecular subtypes of breast cancer [23, 24]. Although the technology is still in its
youth, these approaches, and more importantly, the combination of these approaches
will likely stratify these established subtypes further or give rise to novel subtypes of
breast cancer. This is an important area of research as the sorting and understanding of
all this new information is critical for personalized medicine and the development of new
targeted therapies.

Human genome and long noncoding RNAs (lncRNAs)

Genomic landscape. The central dogma of molecular biology has defined the
linear progression of biological identity and function as “DNA makes RNA, makes
protein.” Translation to protein has traditionally been the requirement for a particular
DNA sequence to be assigned the title of “gene”. The completion of the Human
Genome Project significantly expanded our insight into absolute genomic landscape,
and has allowed for scientists to map and organize ~3 billion base pairs to a more
precise number of protein-coding genes, often cited as 20,000 to 25,000 [25]. RNA has
customarily been reduced to the role of an intermediate, conveniently modified and
processed in a highly regulatory manner, with a sole purpose to relay the appropriate
language for building a functional protein. It is interesting to note however, that when a
more global view of the human genome reveals that only ~1.5% accounts for protein
coding exons, increasing to ~2% if including introns and untranslated regions (UTRs)
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[26]. The vast majority of the remaining uncharacterized genome aside from
housekeeping RNAs was thought not to be expressed and coined “junk DNA,” and this
has served as a suitable designation for some time.
In recent years, however, modern technologies such as tiling arrays, massive
parallel sequencing, and RNA-sequencing have demonstrated that the human
transcriptome is much larger than previously thought, giving rise to a paradigm shift in
molecular biology known as the “RNA Hypothesis” [27-29]. Current estimates now
consider that ~70% of the human genome is transcribed into RNA, a discovery that
provides justification to reconsider what constitutes the functional genome, and place
greater emphasis on what is defined a “gene” [30]. To date, several classes of noncoding RNAs (ncRNAs) have been categorized and well-defined, demonstrating the
diversity and dynamic role of RNA in cellular function (Table 1) [31-33]. A recent
example of this shift is the extensive study and documentation of microRNAs (miRNAs),
a class of small RNAs that illustrate the sophistication RNA potentiates in exerting direct
function in biological processes [34]. The most recent advance has led to the discovery
and rapid characterization of another novel group of ncRNA, termed long noncoding
RNA (lncRNA).

Characteristics of lncRNA. The current and general parameters for defining
lncRNAs are as follows; 1). polyadenylation at 3’ UTR in a majority of lncRNAs, 2).
epigenetic markers including trimethylation at lysine-4 of H3 (H3K4me3) at the promoter
and trimethylation at lysine-36 of H3 (H3K36me3) along transcribed region, 3). active
transcription via RNA polymerase II (RNA pol. II), 4). regulation by established
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transcription factors, 5). processing via canonical exonic splice sites, 6). >200 bp long
without open-reading frame and 7). tissue-specific expression (Fig 1A) [35, 36]. There

Table 1. Species of RNA in the human genome.

Species of RNAs in human genome
Transfer RNAs (tRNAs)
Housekeeping RNAs

Small RNAs
(<200nts)

Ribosomal RNAs (rRNAs)
Small nuclear RNAs (snRNAs)
Small nucleolar RNAs (snoRNAs)
Micro RNAs (miRNAs)
Short interfering RNAs (siRNAs)
Tiny transcription initiation RNAs
Repeat associated small interfering RNAs
Promoter associated RNAs
Retrotransposon derived RNAs
Splice site RNAs
Anti-sense termini associated RNAs

Large RNAs
(>200nts)

Long noncoding RNAs (lncRNAs)
Pseudogenes
Transcribed ultra-conserved regions
Enhancer RNAs (eRNAs)
Repeat associated long ncRNAs

are exceptions however, and examples of non-polyadenylated lncRNAs transcribed via
RNA polymerase III have been reported [37, 38]. The majority of these features emulate
characteristics of messenger RNAs (mRNAs), emphasizing the notion that lncRNAs are
under precise transcriptional control and processed in the same manner as functional
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protein-coding transcripts. The directionality of lncRNA is usually defined in reference to
the nearest protein coding gene, and can exhibit orientations in antisense, bidirectional,
sense, intronic and intergenic (Fig 1B).

Figure 1. The characteristic features and orientation of lncRNAs. (A) There are
several defining features of lncRNAs which distinguishes these transcripts as a class.
(B) LncRNA orientation is defined in relation to the transcriptional start site (TSS) of the
nearest protein coding gene. LncRNA can be transcribed antisense, bi-directional,
sense, intronic, or intergenic orientations. Reproduced from ‘Edward J. Richards and Jin
Q. Cheng, 2014, Long noncoding RNAs and their expanding roles in cancer, Current
Topics in Biochemical Research, Vol. 16, 81 – 95’.
Conservation of lncRNA. The conservation of lncRNAs has been the topic of
extensive debate and study. The significance of linking these attributes to lncRNA would
provide strong evidence for functionality suggesting these transcripts were retained
through selective pressures. By and large, however, lncRNAs exhibit poor sequence
conservation across species in comparison to protein coding genes and microRNAs [39,
40]. One study reported that in starting with a pool of tissue specific human lncRNAs,
80% contained an ortholog transcript in chimpanzee, and this decreased to only 39% in
10

mice [41]. Thus, given the fact that the protein coding genome is almost entirely
conserved across higher organisms, the noncoding genome likely is a key contributor to
species identity and complexity. From an evolutionary perspective, it has been
suggested that lncRNAs are rapidly evolving regulatory elements of high plasticity
responsible for continually mobilizing mammalian evolution [40]. This concept is very
striking given the short evolutionary distance between humans and chimpanzee, and
lncRNAs account for about half the genetic differences between the two genomes [42].
It is also important to remember that selecting for a protein coding gene and
lncRNA needs to be considered independent and mutually exclusive processes.
Conservation of a functional protein coding gene requires high sequence preservation
to ensure proper amino acid coding and secondary protein folding. Any disruption in
sequence can drastically alter the biological function of a protein, and likely this
contributes to the high conservation of proteins across several species. On the contrary,
lncRNAs do not require significant sequence retention along the entire body of the
transcript to retain appropriate architecture and secondary structure necessary for
function. LncRNA function can occur through a protein binding site, a miRNA seed site,
mRNA recognition sequence, or DNA binding element, all of which require relatively
short stretches of sequence for utility. A prime example is the X-inactive specific
transcript (XIST), a 17-kb transcript in human in which conservation is only retained in
exon 1, and this conserved region is critical for proper function [43]. Also, despite a lack
of lncRNA sequence conservation in and of itself, the promoters of lncRNAs
demonstrate very high sequence conservation and are capable of binding established
transcription factors [44].
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Mechanisms of lncRNA Function

Epigenetic and chromatin modification. LncRNAs can regulate gene
expression within a few megabases along the same chromosome or from a distance at
a different chromosome. This regulation is referred to as acting in “cis” and in “trans”,
respectively (Figure 2). The XIST is a very well studied lncRNA that functions in “cis”. In
developing mammalian females, X-chromosome inactivation is a critical compensatory
mechanism to ensure gene dosage equivalency between males and females along the
X-chromosome. XIST mediates this process through its exclusive expression on the
inactive X-allele via the X-chromosome inactivation center (Xic) [43, 45]. The first exon
of XIST contains a double hairpin motif capable of binding polycomb recessive complex
2 (PRC2), and recruitment of this histone methyltransferase complex results in trimethylation of lysine 27 at H3 (H3K27me3) and transcriptional silencing along the
inactive X-chromosome [46]. Interestingly, the active X-chromosome represses XIST
expression through interaction with an antisense lncRNA known as TSIX, yet an exact
mechanism has yet to be determined for this modulation [47].
One of the better characterized lncRNAs that functions in epigenetic and
chromatin modification in “trans” is HOX antisense intergenic ncRNA (HOTAIR).
HOTAIR is located on chromosome 12 and is oriented antisense to the HoxC cluster,
and transcriptionally represses the HoxD locus on chromosome 2 [48]. There are two
functional domains of HOTAIR, a PRC2-binding domain at the 5’ end which interacts
with subunit Suz12, and an LSD1/CoREST1-binding domain at the 3’ end. It is
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suspected that these two complexes use HOTAIR as a modular scaffold for
collaboration and recruitment to target gene locations [49]. The precise mechanisms for

Figure 2. LncRNA functions in “cis” or in “trans”. LncRNAs that function locally on
the chromosome of origin are referred to as functioning in “cis”. This is the case of XIST,
which is transcribed at X-chromosome inactivation center (XIC) and is responsible for Xchromosome inactivation. LncRNAs can also regulate target gene expression on distant
chromosomes in “trans”, such as HOTAIR which is transcribed from HoxC gene cluster
on chromosome 12, yet represses target HOXD expression on distant chromosome 2.
Reproduced from ‘Edward J. Richards and Jin Q. Cheng, 2014, Long noncoding RNAs
and their expanding roles in cancer, Current Topics in Biochemical Research, Vol. 16,
81 – 95’.

how “trans” functioning lncRNAs target specific genes on distant chromosomes are still
not well understood. There have been several additional mechanisms reported for
lncRNA function (Table 2).
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Table 2. The biological mechanisms of lncRNA function.

Mechanisms of lncRNA function
Function

Specific lncRNA mechanism

Reference

Epigenetic and chromatin
modification

XIST: Exclusively expressed on the inactive X
chromosome, recruits PRC2 to X-chromosome
inactivation center (XIC) for gene silencing

43

Sponge for miRNAs

H19: Contains 4 Let-7 binding sites throughout
transcript body to competitively bind and downregulate Let-7 in Ago2 dependent manner.

51

ZEB2-AS: Transcribed antisense to ZEB2 mRNA,
binds ZEB2 transcript and prevents splicing of 5’
intron preventing protein translation.

57

CCAT2: Transcribed in enhancer region ~334 kb
upstream of C-MYC transcriptional start site,
recruits TCF7L2 to C-MYC promoter.

61

PANDA: Induced in DNA damage response, binds
and sequesters transcription factor NF-YA to
prevent induction of pro-apoptotic gene targets

63

Messenger RNA processing and
protein translation

Enhancers and transcriptional
activation

Decoy for protein binding

Reproduced from ‘Edward J. Richards and Jin Q. Cheng, 2014, Long noncoding RNAs
and their expanding roles in cancer, Current Topics in Biochemical Research, Vol. 16,
81 – 95’.

Sponge for miRNAs. It is becoming more apparent that some lncRNAs contain
multiple miRNA response elements (MREs), which layers ncRNA regulation through
competition. This theory is known as the competing endogenous RNA (ceRNA)
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hypothesis [50]. LncRNAs can interact with miRNAs through these repeat MREs along
the length of the transcript to influence global gene expression. For example, within the
body of lncRNA H19 resides 4 canonical and noncanonical MREs for Let-7 [51]. It was
demonstrated that enforced expression of H19 results in more Let-7 binding at these
MREs in an Ago2-dependent manner. Through competitive binding and sequestering of
Let-7, downstream targets of Let-7 such as DICER and HMGA2 increased their
expression [51].
Linc-ROR, a regulator of reprogramming, can also act as a sponge and shares
MREs with several miRNAs that target the core transcription factors in maintaining
embryonic stem cells. [52, 53]. Expression patterns of linc-ROR are consistent and
associate with undifferentiated status. Linc-ROR contains MREs for miR-145, miR-181,
and miR-99-3p, which target Oct4, Nanog, and Sox2. Enforced expression of linc-ROR
competitively binds these miRNAs relieving target repression, enhancing protein
expression of these core transcription factors. Loss of linc-ROR leads to decreased
expression of Oct4, Nanog, and Sox2 and movement towards the differentiated state
[53].

Messenger RNA Processing and Protein Translation. LncRNAs can
physically interact with mRNAs to influence stability of the transcript or translation in
dynamic ways [54, 55]. This relationship is especially apparent in the case of protein
coding genes which contain overlapping natural antisense transcripts (NATs). Uchl1
protein gene overlaps with antisense lncRNA Uchl1-AS at the 5’ region and also
contains an inverted SINE2B repeat element downstream [56]. In the stress response or

15

using rapamycin treatment to induce stress, Uchl1-AS will rapidly shuttle from the
nucleus to the cytosol where it binds to and stabilizes the Uchl1 mRNA transcript along
the 5’ UTR region leading to increased translation. The detailed underlying mechanism
is not very well understood, but the SINE2B element is critical for enhanced translation
during this process, indicating a possible novel function for transposable elements
within the genome [56].
In another example, Snail1-induced epithelial to mesenchymal transition (EMT)
does not activate Zeb2 mRNA transcription, but rather promotes Zeb2 translation
through splicing of a large intron at the 5’ UTR region. This intron contains an internal
ribosome entry site (IRES) necessary for the expression of Zeb2. Maintenance of 5'UTR Zeb2 intron is dependent on the expression of Zeb2-AS1 that overlaps the 5' splice
site in the intron. In the non-EMT state this intron is spliced out, which does not affect
mRNA level yet does prevent protein translation. In the case of Snail1-induced EMT,
Zeb2-AS1 is transcribed and its complimentary base pairs with the 5’ UTR of Zeb2
prevents splicing of the 5’ IRES sequence allowing for Zeb2 translation [57].

Enhancers and transcriptional activation. Enhancers are regulatory DNA
elements that activate gene transcription in “cis” through chromosomal looping and
recruitment of cofactors [58, 59]. It is now emerging that these regulatory regions
frequently contain lncRNAs which have target gene specificity and promote cofactor
recruitment. In one study, enhancer-associated ncRNA-a7 was characterized as being
able to specifically regulate SNAI1 transcription, yet had no relationship to RNF114,
UBE2VI, TMEM189, or CEBPB which reside within the same 100 kb radius [60]. It was
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also shown that SNAI1 migration phenotype was driven through ncRNA-a7 providing
strong evidence that lncRNAs play a key regulatory role in gene expression and
downstream biological processes [60].
Another

lncRNA CCAT2,

which locates ~334

kb

away from C-MYC

transcriptional start site, was shown to be over-expressed in colorectal cancers and
promote chromosomal instability, invasion, and metastasis [61]. CCAT2 binds to
transcription factor TCF7L2 for recruitment to the enhancer region and results in
activation of C-MYC transcription through chromosomal looping and interaction at the
promoter. Interestingly, CCAT2 has a single nucleotide polymorphism (SNP) that
associates with increased risk of developing colon cancer. This study suggests that this
SNP is functional through the RNA product, and enhances TCF7L2 recruitment to the
C-MYC promoter prompting a paradigm shift that SNPs are typically functional through
DNA elements [61].

Decoy for protein binding. LncRNAs can also function as decoys through
binding protein targets and thereby preventing normal function and localization of the
protein. For example, in response to DNA damage a subset of lncRNAs will be induced
in a p53-dependent manner including 2 bidirectional transcripts upstream of the p21
promoter, lincRNA-p21 and PANDA [62, 63]. During this response PANDA will bind to
the transcription factor NF-YA and prevent its localization at promoters of pro-apoptotic
target genes. Thus, PANDA allows for cell cycle arrest and DNA repair rather than
programmed cell death in the p53 response [63]. Another example can be seen in extracoding CEBPA lncRNA (termed ecCEBPA), a ~4.5kb transcript encompassing the
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entire ~2.6 kb portion of the CEBPA gene in the sense direction [64]. When ecCEBPA is
expressed it will competitively bind and exclude DNMT1 for the occupying chromatin at
the CEBPA promoter, thus preventing DNA methylation and activating transcription of
the CEBPA [64].

LncRNAs in Cancer and Malignancy

LncRNAs regulate genes that participate in a wide range of biological processes,
and for this reason they can act as oncogenes and tumor suppressors. Aberrant
expression of lncRNA can be a deciding point in cancer etiology, promote tumor onset
and disease progression, as well as drive metastasis. LncRNAs are also a novel and
untapped resource for pathological and clinical utility for use as novel biomarkers.
Although a number of lncRNAs have been associated with cancer in literature, there is a
clear need for further identification and characterization of more candidates. The
following section will discuss the function and clinical significance of specific lncRNAs
reported in human cancer to date.

HOTAIR. HOTAIR, as discussed above, locates on chromosome 12 and is
responsible for “trans” silencing the HoxD genes of chromosome 2 through recruitment
of PRC2 complex [48]. HOTAIR expression has been shown to be up-regulated in both
primary and metastatic breast cancers, in some cases as high 2,000-fold overexpression. Furthermore, the elevated expression correlates with increased risk of
metastasis, as well as poor metastasis-free and overall survival [65]. In vitro studies
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demonstrate that knockdown of HOTAIR can inhibit invasive capacity. While in vivo,
enforced expression of HOTAIR results in a greater capacity for breast cancer cells to
colonize the lung following tail vein injection [65].
In non-small cell lung cancer (NSCLC), HOTAIR has been shown to have
elevated expression levels when comparing 42 lung carcinomas to matched normal
tissues [66]. Elevated HOTAIR in NSCLC patients also associates with late stage tumor,
positive lymph node metastasis, and poor overall survival. This study also demonstrates
that HOTAIR can control cell migration, invasion, and metastasis in vitro and in vivo,
and shows that knockdown of HOTAIR leads to apoptosis. Depletion of HOTAIR
resulted in significant loss of expression of known metastasis promoting genes MMP2
and MMP9, and increased expression of HOXA5, which has been shown to be
important in inhibiting lung cancer metastasis [66].
A recent study shows that in renal carcinoma cells HOTAIR is inversely
correlated in expression with miR-141 [67]. This study also shows that HOTAIR plays a
critical role in promoting migration, invasion, and survival in renal carcinoma.
Interestingly, enforced expression of miR-141 results in significant loss of HOTAIR
expression,

reduced

invasive

phenotypes,

and

increased

apoptosis.

Further

investigation revealed that HOTAIR is a bona fide miR-141 target in an AGO2
dependent manner. This study illustrates the dynamic relationship between ncRNA
species regulating each other, and their potential role in kidney cancer [67].

XIST. In one study the contribution of XIST to hematological cancers using a
conditional knockout mouse model was evaluated. The majority of the females in which

19

XIST is conditionally removed from cells in the blood compartment results in aggressive
and

rapid

onset

of

multi-lineage

hyperproliferations,

myelodysplasia,

and

myeloproliferative neoplasms [68]. These results suggest a potent tumor suppressor
role for XIST in hematopoietic stem cells and potentially other tissues. Deletion of XIST
resulted in X chromosome reactivation and aberrant gene expression in several major
tumor suppressive pathways contributing to the rapid onset of disease [68].
A second study used microarray technology to compare global changes in RNA
expression in primary ovarian tumor to recurrent ovarian tumors after chemotherapy
[69]. Interestingly, in recurrent ovarian cancer XIST was the most significantly
downregulated gene in comparison to primary tumor [69]. From a therapeutic standpoint,
this suggests that XIST can potentially play a role in sensitizing patients to taxol and
cisplatin based chemotherapies. XIST can also serve as a marker for chemoresistant
ovarian cancer.
XIST has also been linked to the BRCA1 tumor suppressor gene in patients with
breast or/and ovarian cancers. Initial reports indicated that breast cancers with deficient
BRCA1 expression or function have defects in X chromosome inactivation, and
enforced expression of BRCA1 gene can initiate XIST expression [70]. This view was
later challenged using a BRCA1 conditional knockout mouse model which
demonstrated that depleting BRCA1 had no affect on X inactivation and gene dosing, as
well as showed no evidence of BRCA1 and XIST colocalization [71]. The relationship
between BRCA1 and XIST in breast cancer will require future investigation to be better
established.
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MEG3. Maternally expressed gene 3 (MEG3), a paternally imprinted gene
comprised of 10 exons, is expressed in many normal tissues [72]. There are 12 different
MEG3 gene transcripts, generated by alternative splicing. They contain the common
exons 1-3 and exons 8-10, but each uses one or more exons 4-7 in a different
combination in the middle. All MEG3 RNA isoforms contain three distinct secondary
folding motifs M1, M2, and M3 that are critical for activation of p53. MEG3 isoform
expression patterns are tissue and cell type specific. However, each isoform stimulates
p53-mediated transactivation and suppresses tumor cell growth.

MEG3 retains the

ability to activate p53 in spite of replacing regions unrelated to M1, M2, or M3, thus
provides evidence that a proper folding structure of the MEG3 RNA molecule is critical
for its biological functions and that only short stretches of sequence conservation are
vital to maintain function [73]. In addition to transcriptionally activating p53, MEG3 can
also enhance binding of p53 at target gene promoters including GDF15 [74]. MEG3
expression is dramatically lost in several human cancers [73]. Reintroduction of MEG3
into NSCLC cells was able to slow colony formation capacity and cell proliferation [73].
In panel of hepatocellular carcinoma (HCC) cells MEG3 is frequently
downregulated, and enforced expression of MEG3 was able to slow cell proliferation,
inhibit anchorage independent growth, and promote apoptosis [75]. This same study
also demonstrated that maternal allele of MEG3 is hypermethylated in a DNMT1 and
DNMT3b dependent manner. Interestingly, miR-29a expression is also commonly lost in
HCC and DMNT1 and DNMT3b are direct targets of miR-29a. Loss of miR-29a results
in aberrantly increased DMNT1/3b expression in HCC and provides a novel mechanism
for MEG3 downregulation due to hypermethylation at the promoter [75].
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ANRIL. Antisense noncoding RNA in the INK4 locus (ANRIL) was initially
identified as being deleted in the germ-line deletion of the 9p21 gene cluster [76]. This
gene cluster contains several important tumor suppressor genes including, p14ARF,
p15INK4B, and p16INK4A that are deleted along with ANRIL across ~ 403 kb region
and results in cancer predispositions [77-79]. ANRIL locates in the antisense direction
and overlaps with the p14ARF promoter and 2 exons of the p15INK4B gene body [76].
Although initial reports identified this transcript as associated with deletion, later reports
suggest that ANRIL over-expression can also drive cancers [80, 81].
Elevated expression of ANRIL was detected in prostate cancer and inhibiting
ANRIL expression resulted in increased INK4A and INK4B gene products, denoting a
transcriptional repression in “cis”. In this same study it was shown that ANRIL can bind
to CBX7 component of the PRC1 repressive complex and epigenetically silence the
associated tumor suppressive genes on 9p21 gene locus [80]. ANRIL is also elevated
human gastric cancers and associates with poor overall survival. This same study
demonstrated that ANRIL can silence oncogenic miRNAs, including miR-99a and miR449a, through binding to the components of PRC2 transcriptional repression complex
[81].

Emerging lncRNAs in cancer. The 8q24 chromosomal amplification associates
with increased risk for several cancers. Linked within this region resides a gene desert
containing no protein coding genes in addition to the C-MYC oncoprotein [82-85].
Several lncRNAs (CCAT2, Carlo-5, and PVT1) have been identified within this region
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and regulate C-MYC expression through a variety of mechanisms including
transcriptional activation, enhancer-associated function, and protein stability [61, 86, 87].
Another interesting lncRNA, FAL1, has recently been identified as locating in a
focally amplified chromosome 1q21 region across several epithelial cancers including
breast and ovarian [88]. FAL1 binds to PRC1 core subunit BMI1 to transcriptionally
repress tumor suppressor gene p21. Interestingly, FAL1 is a predictor of poor overall
survival in ovarian cancer patient and elevated FAL1 closely associates with
chromosome 1q21 DNA copy number gain [88].
TGFβ-induced lncRNA-ATB is also emerging as an important driver in EMT and
metastasis in liver cancer. LncRNA-ATB is a potent driver of the EMT by acting as
miRNA sponge for the miR200 family [89]. This family is the master regulator of ZEB1/2
expression through 3’ UTR mediated repression in an Ago2 dependent manner. Also,
lncRNA-ATB promotes cell proliferation and distant colonization through directly binding
and stabilizing IL-11 mRNA resulting in activation of phospho-STAT3 [89].

TGFβ Signaling Pathway

TGFβ Signaling Pathway and Ligands. The TGFβ signaling pathway is
dynamic and involves in a variety of normal cellular programs such as cell differentiation,
proliferation, inflammation, tissue morphogenesis, regeneration, and maintenance
(Figure 3). It has become clear that TGFβ pathway is dependent on cellular context. For
example, depending on cell type and tissue of origin the TGFβ pathway can elicit a
radically different, and sometimes opposite functional response [90]. Significant
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research efforts have been put forth in defining the related cytokines, receptors, and
intracellular signaling molecules in order to establish the pathway, which made it
possible to study its functional role in a given cellular context. We now have a better
understanding of the pleiotropic effects elicited by the TGFβ pathway.
The TGFβ related ligands and cytokines consist of 2 subfamilies (including 42
ligands and over 300 target genes) as categorized by sequence homology and
downstream effectors in the pathway [91]. The first family includes the TGFβ’s, Activin,
and Nodal ligands, while the second family consists of the BMPs (bone morphogenetic
proteins) and MISs (muellerian inhibiting substances) [92]. Both families work in a
variety of developmental cellular functions such as embryogenesis, osteogenesis, and
hormone regulation. [93-95] The TGFβ monomer contains a conserved “cysteine knot”
which consists of several beta strands held together by three tight disulfide bridges.
These monomers typically take on the active dimerized form that is held via
hydrophobic interactions and disulfide bridges. [96] Ligand traps are a group of proteins
that regulate the TGFβ ligands and cytokines access to receptors. These traps can
promote or inhibit the ligand/receptor interaction and provides a mechanism of
specificity. [97]

TGFβ Signaling Pathway Receptors. The receptors associated with TGFβ
pathway are serine/threonine kinases and are referred to as type I (7 receptors) or type
II (5 receptors). These receptor kinases contain an extracellular N-terminal ligand
binding domain, a transmembrane domain, and a C-terminal kinase signaling domain.
Type I receptors are 53-KD proteins that contain a conserved SGSGSG motif, called
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GS domain, located N-terminally and in close proximity to the kinase domain. This
domain on type I receptor is directly phosphorylated by type II receptor resulting in
activation of dimeric complex, and therefore a heterodimer is critical for activation. [98]
There are 2 distinctive ligand-receptor interactions which are distinguished by the 2
superfamilies of ligands mentioned above. These distinctions refer to each subfamilies
affinity to TGFβ receptor types, for example TGFβ’s, Activins, and Nodal ligands
preferentially bind to type II receptor and do not interact with isolated type I receptors,
while BMPs prefer to interact and have high affinity for type I receptors. [99]

TGFβ Signaling Pathway SMAD Proteins. The intracellular effector and
regulatory molecules of the TGFβ pathway are the SMAD family proteins. Three classes
of SMAD proteins exist in humans, receptor regulated SMADs or “R-SMADs” (includes
SMAD1, 2, 3, 5, 8/9), co-mediator SMAD or “co-SMAD” (SMAD4), and inhibitory SMAD
or “I-SMADs” (SMAD6, 7) (Figure 4). R-SMADs are the direct substrates of receptor
mediated phosphorylation by type I receptors. SMAD2 and SMAD3 are activated in
response to TGFβ ligand subfamily, while SMAD1, SMAD5, and SMAD8 respond to
BMP subfamily of ligands. [92]
R-SMADs are typically about 400-500 amino acids, contain a conserved Nterminal MH1 (MAD-homology 1) domain (40-95% conservation across R-SMADs), Cterminal MH2 (MAD-homology 2) domain (38-98% conservation), and have 2 conserved
structural domain to provide secondary structure. [100] The MH1 domain functions as
the DNA recognition and binding element while MH2 domain facilitates homo- or hetero-
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Figure 3. The TGFβ signaling pathway and associated molecules. The TGFβ
pathway consists of ligands, receptors, and intracellular signaling molecules called
SMADs to influence target gene expression. The TGFβ (transforming growth factor
beta) and BMP (bone morphogenic protein) ligands bind type I and II TGFβ receptors to
initiate R-SMAD (regulatory) and co-SMAD (cooperative) signaling cascade. Inhibitory
SMADs (I-SMADs) can directly bind to and inhibit the receptors through a negative
feedback loop.

oligermization to promote dimer activation. The R-SMADs also contain an SXS motif at
the C-terminal region and these serine residues are critical for activation [101]. Two
members of the Hecht-family of E3 ubiquitin ligases, SMURF1 and SMURF2, can target
and negatively regulate the R-SMADs and receptors [102, 103]. Subsequent R-SMAD
activation via type I or type II TGFβ receptor, homo-oligomerization will first occur, and
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downstream with co-SMAD4 as a hetero-dimer or -trimer. The active heterocomplex of
R-SMAD/co-SMAD4 can then translocate to the nucleus and activate transcription of
numerous target genes. Target gene transcription and functional outcome occurs
through the dynamic interactions with the MH1 and MH2 domains as well as the
recruitment of other transcriptional mediators.
Negative regulation of the TGFβ pathway is a critical feedback process and
tightly regulated mechanism to haul over-active signaling. Two members of the Hechtfamily of E3 ubiquitin ligases, SMURF1 and SMURF2, can target and negatively
regulate the R-SMADs and type I and II receptors [103]. Specifically SMAD1 and
SMAD5 is a substrate for SMURF1 ubiquitin ligase activity. [104] SMURF2, which
contains significant homology to SMURF1, can preferentially inhibit SMAD1 and
SMAD2 [105, 106]. Inhibitory SMAD7 plays a critical role as co-regulator in this process.
Once TGFβ pathway is activated, SMAD7 will translocate from the nucleus to the
cytosol to locate at the plasma membrane through an unknown mechanism. As a result
of this translocation, SMAD7 can form complexes with both SMURF1 and SMURF2 and
become tethered to the membrane to directly bind type I receptors, including those
involved in the late endosomal compartments. Binding of SMAD7 to type I receptor will
competitively inhibit phosphorylation of R-SMADs [106]. Also, recruitment of SMURFs to
the membrane will promote E3 ubiquitinase activity to directly facilitate degradation of
the receptors. This negative feedback look is perpetuated and balanced given that
during TGFβ activation SMAD7 is itself ubiquitated and degraded, yet is also a
transcriptionally activated target gene [108]. This ensures proper SMAD7 turnover and
dosage during the response.
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Figure 4. The SMAD family of proteins. The SMAD family is comprised of R-SMADS
(regulatory), Co-SMAD (cooperative), and I-SMAD3 (inhibitory) and function through
varying regions N-terminal MH1 domain (MAD homology-1), middle linker region, and
C-terminal MH2 domain. Abbreviations: NLS (nuclear localization signal), P-Y (prolinetyrosine), SXS (serine-X-serine), NES (nuclear export signal), SAD (SMAD activation
domain). Figure adapted from Moustakas et. al. [107].

TGFβ-associated phenotypes and genes

Epithelial to Mesenchymal Transition (EMT). The epithelial to mesenchymal
transition (EMT) is a highly organized process facilitated through distinct biological
pathways that shift a polarized epithelial cell to a mesenchymal phenotype.
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Mesenchymal phenotypes associate with increased motility and invasion,
production of extracellular matrix components (fibroblast-like), and resistance to
apoptosis [109, 110]. EMT exemplifies the inherent ability of epithelial cell plasticity and
how dynamic interactions from extracellular components can influence terminally
differentiated tissue to promote cancer phenotypes. Ultimately, this process is the
driving force in which a cancer cells can degrade the basement membrane and gain
access to the blood stream and initiate metastasis (Figure 5).
It is important to note that the process of EMT is initial breaching of the basement
membrane and escape from the primary site. Downstream, other process such as
resistance to anoikis (anchorage-independent cell death) and mesenchymal to epithelial
transition (MET) must still take place for a cell to successfully colonize and form a
secondary carcinoma. The process of EMT is considered a fundamental hallmark of
cancer, and further understanding this process is critical given the consequences that
once cells leave the primary site acquire these aggressive characteristics to enable
metastasis [111].

Changes in Gene Expression Associated with EMT. There are several
fundamental gene changes associated with conversion of an epithelial cell to more
mesenchymal cell. Down-regulation of cell to cell adhesion and tight junction molecules
like e-cadherin (CHD1) and ZO-1 which stabilize and immobilize the epithelium is
typically characteristic to early EMT. This down-regulation is also true for several other
more

specific

cytoskeletal and

adherent

molecules

like

claudins,

occludins,

desmoplakins, and cytokeratins [112]. At the same time as there is a loss of adherent
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Figure 5. The epithelial to mesenchymal transition (EMT) in breast cancer. In
breast cancer progression, the normal epithelial cell layer within the breast duct will
become hyperplastic and eventually lead to an uncontrollable proliferative mass known
as carcinoma. The primary carcinoma will fill the duct while at the edge of the tumor
some cells will break through the basement membrane. These cells are considered to
have undergone the epithelial to mesenchymal transition (EMT). These invasive cells
can gain access to blood vessels and travel to distant organs in the body to colonize
and form secondary carcinomas. This process is referred to as mesenchymal to
epithelial transition (MET) and metastasis. Adapted from Kalluri and Weinberg [110].
molecules, there is an up-regulation of another set of molecules responsible for motion
and invasive potential. There is a “cadherin switch” from E-cadherin to N-cadherin
expression which decreases cell to cell contact. The up-regulation of N-cadherin not
only affects adhesion qualities on cell surface, but also shifts signaling pathways inside
the cell to promote migration and invasion. These pathways and interactions include βcatenin, receptor tyrosine kinases (RTKs), platelet derived growth factor (PDGF),
fibroblast growth factor receptors (FGFRs), and SRC family kinases [113-115]. In
addition, several other genes such as vimentin, fibronectin, collagen I/IV, lamin I, and
matrix metalloproteinases MMP2/MMP9 are up-regulated enhancing cell’s ability to
break through the basement membrane and ECM components (Figure 6) [104].
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There are also several established transcription factors that drive EMT including
ZEB1/2, SNAI1, and basic helix loop helix transcription factors (bHLH). ZEB1/2 can
transcriptionally repress or activate several target genes to promote EMT in cancer
through it’s interaction with DNA regulatory sequences called E-boxes [116]. ZEB1 can
interact with c-terminal-binding protein (CTBP) or switch sucrose/non fermentable
protein (SWI/SNF) protein BRG1 to transcriptionally repress e-cadherin [104]. SNAI1
(SNAIL) and SNAI2 (SLUG) are known to drive mesenchymal phenotype during
embyrogenesis and development and can become reactivated in cancer [117].
Similar to ZEB1/2 function, SNAI1/2 can bind to E-boxes through their zinc finger
motifs to shut down E-cadherin transcription. Once bound to E-cadherin promoter,
SNAIL can recruit polycomb recessive complex 2 (PRC2) which contains several
subunits histone methyltransferase, histone demethylases, histone deacetylases, and
co-repressors. Together the subunits of PRC2 work through modifying histones and
chromatin to coordinate transcriptional repression [104]. The bHLH transcription factors
that play a major role in contributing to EMT are TWIST1 and TWIST2. TWIST1/2 can
repress E-cadherin expression independently from SNAIL and also transcriptional
activate several mesenchymal genes such as N-cadherin [116]. All three of these
transcription factors can be up-regulated via several mechanisms associated with tumor
proliferation and tumor microenvironment, including but not limited to elevated levels of
TGFβ, hypoxia inducible factor 1α (HIF1α), WNT signaling pathway, and RAS-MAPK
signaling pathway [118-121].
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Figure 6. EMT-associated markers and phenotypes. Throughout the process of EMT
gene signatures and cell phenotype will change from epithelial status to a more
mesenchymal state. Characteristic expression of epithelial markers such as e-cadherin,
ZO-1, and specific cytokeratins will be down-regulated, and the TGFβ-induced transition
with trigger a switch towards mesenchymal markers such as vimentin, fibronectin, and
Zeb1/2. The epithelial cells will phenotypically appear more spindle-like, contain fewer
tight junctions, and become more motile and invasive.

Cancer Stem Cells (CSCs). Historically, clinicians have observed in that giving a
single agent therapy to a patient a subset of cells in the primary tumor are sensitive to
the treatment while others remain resistant. It is now established that a primary tumor is
not composed of a monoclonal mass of cells with equal cellular make-up and
constituents, but rather tumor heterogeneity exists within the mass [122]. In fact a
primary tumor is not only composed of genetically and phenotypically distinct carcinoma
cells, but is also composed of endothelial, stromal, immune, and hematopoietic cells
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that function as a dynamic system. Terminally, well-differentiated epithelial cells are
typically thought of as being functional, healthy adult tissue. Therefore, the term “cancer
stem cell” in part refers to cancer’s ability to revert from this well-differentiated state
back to a more “stem-like” state. A loose definition for CSCs is a population of cancer
cells that can be isolated with a capacity for long-term repopulation and self-renewal of
the original tumor. [123, 124]
Functionally, CSCs can initiate tumor formation in xenograft model, self-renew
through serial passaging of spheres, and spawn daughter cells which can proliferate
and also form new tumor, although this tumor is may be different from parental [104,
125]. The origin of CSCs remains up to debate and several theories have surfaced. One
known as the hierarchal model proposes that a small subset of CSCs exists within the
tumor population, and these cells obtain the characteristics for tumor propagation as
well as self renewal of more CSCs. In contrast the stochastic model assumes that all
cells within the tumor have the ability for tumor initiation and these qualities are
intrinsically determined by several factors and influenced by surrounding environment
(Figure 7) [124].

Breast Cancer Stem Cells (BCSCs). BCSCs originate in the breast and obtain
the properties described above. Initial reports of BCSCs utilized cell surface markers
CD44 and CD24 status to distinguish the stem cell population. BCSCs are typically
defined as population of cells that is CD44+/CD24-. In one study, total breast cancer
cells from human patient tumor were sorted for CD44+/CD24- population or cells
without this surface receptor status. In eight out of nine patients as few as 100 cells
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isolated with CD44+/CD24- were able to establish a xenograft tumor in mice, while tens
of thousands of cells were required if there was alternate cell surface status [126]. The
classification of BCSCs based solely on CD44 and CD24 status remains up to debate,
as several reports claim that elevated CD24 associates with poorer patient outcome
[127, 128]
Another cellular marker that is widely used to distinguish BCSCs as well as other
CSCs is alcohol dehydrogenase isoform 1, ALDH1. This enzyme normally catalyzes
oxidation of intracellular aldehydes in the process of normal stem cell differentiation
[129]. Interestingly, the population of ALHD1+ cells sorted from total CD44+/CD24population is only about 1%. However, if CD44+/CD24- population is also then sorted
for ALDH1+, these cells obtain ~5-fold greater tumor initiating capacity as compared to
those sorted for CD44+/CD24- alone [130]. In addition to this, it has been reported that
patients with elevated levels of ALDH1 in tumor have overall poorer survival [131].
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Figure 7. The “Stochastic” and “Hierarchal” models of cancer stems cells. (CSCs).
There are 2 theories that exist for CSCs referred to as stochastic and hierarchical
models. The stochastic model suggests that cancer cells are dynamic, and through
gene expression changes any cell can acquire properties necessary to initiate de novo
tumor formation. The hierarchal model suggests that the CSCs are more static and fixed,
and only a few distinct cells obtain the potential to be tumor initiating.
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CHAPTER 2
Identification of lncRNAs regulated by TFGβ in mouse mammary epithelia and
strategy to identify human orthologs

Introduction

It has been well documented that metastasis is the most common cause of death
from human cancer. TGFβ has been shown to play a pivotal role in cell migration,
invasion, EMT and metastasis. A number of protein coding genes and miRNAs have
been shown to be regulated by TGFβ and mediate TGFβ action and phenotypes.
However, lncRNAs regulated by TGFβ and their role in EMT and tumor metastasis has
not been well documented.
The miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) is
now well established as a key negative regulator of EMT through targeting ZEB1 and
ZEB2, considered to be key drivers in the process [132, 133]. Interestingly, ZEB1 can
also negatively feedback on miR-200 family through direct binding to the promoter
regions and transcriptionally repress expression through the recruitment of co-factors.
[134] Although loss of miR-200 family results in increased EMT and intravasation from
primary site, in a not well understood process re-expression of miR-200 has been
shown to be critical for MET and colonization at distant site. For example, there is
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higher miR-200 expression in the highly metastatic mouse cell line 4T1, which is
capable of colonizing and forming macrometastases, compared to 4T07 which can form
micrometastases but not colonization. Ectopic expression of miR-200 in 4T07 cell line
enhanced MET and formation of macrometastasis at distant site, primarily through
targeting Sec23a [135, 136]. Other miRNAs such as MYC induced miR-9, TGFβ
induced miR-155, and miR-221/222 cluster have been shown to be potent promoters of
EMT through direct targeting of E-cadherin, RHOA, and TRPS1 [137-139]. In 2008, the
first connection between lncRNA, Zeb2-AS, as a mediator of EMT was elegantly
described (mentioned above). Recently, a TGFβ-activated lncRNA, lncRNA-ATB, has
been shown to play an important role in TGFβ-mediated EMT by acting as a sponge for
miR-200 family. LncRNA-ATB is significantly up-regulated in response to TGFβ and
contains 3 bonafide miRNA binding sites for miR-200. These sites can act as a miRNA
sponge to bind and sequester miR200s, and provide a novel mechanism for ZEB1/2 upregulation and initiate EMT [89].
Noncoding RNAs can have a significant influence in the biological processes
associated with cancer stems cells such as pluripotency, self renewal, and
differentiation. In several cancers, including pancreatic, prostate, and gastric, the p53induced miR-34 family (miR-34a, miR-34b, and miR-34c) has demonstrated to suppress
tumor formation and tumor initiating cells [140-142]. miR-34 directly targets several key
tumor promoting genes which likely all contribute to inhibiting this process, such as
CD44, C-MYC, BCL-2, MET, CDK4/6, and Cyclin E2 [140, 141, 143-145]. Let-7 and
miR-200c have also been shown to be down-regulated in CSCs compared to
differentiated state and non-CSC tumor cells [146, 147]. The functional role of lncRNAs
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contributing to CSCs has not been very well studied and established. However, there
are certainly candidate lncRNA genes that can contribute to tumor initiating population
given there implications in other studies. For example, lncRNA H19 acts a miRNA
sponge for Let7-family and inhibit Let-7 function leading to upregualtion of Let-7 target
genes. [51] Given that let-7 loss has previously been implicated in driving CSCs, H19
likely contributes to this process.
It is well established that the NMuMG cell line undergoes EMT and takes upon
more fibroblastic features if treated with TGFβ for 24 hours. We have isolated total RNA
from NMuMG cells treated with vehicle (DMSO) or TGFβ for 24 hours. The RNA was
reverse transcribed, end-labeled with digoxigenin, and hybridized to NCode Mouse
Non-coding RNA Microarray (Invitrogen). This microarray contains high-density oligo
based probes designed to interrogate 10,802 unique putative mouse lncRNAs, as well
as 25,179 mRNAs from the RefSeq database.
Although the majority of lncRNAs are not conserved from mouse to human, we
hypothesized that a small fraction of them are conserved and have a strong functionality.
Retention of sequence through evolutionary pressures has been very important for
preservation of structure and function in proteins, and it is possible this same
occurrence has taken place among lncRNAs. Furthermore, of the significantly induced
lncRNAs by TGFβ in mouse, we implemented a system based on 4 criteria to predict a
strong potential for ortholog lncRNA in human. Using this strategy, we were able to
successfully predict 10 human ortholog lncRNAs and detect expression of 9. Three of
these transcripts were also regulated by TGFβ in human primary mammary epithelial
cell line HMEC. We further investigated these transcripts.
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Results

Profile of lncRNA expression in TGFβ-induced EMT in NMuMG cells. Using
the widely employed NMuMG mammary epithelial cells as a model to study TGFβinduced EMT, we have previously shown that TGFβ up-regulates ncRNA BIC, which
processes into miR-155 to contribute to the process of EMT [138]. Therefore, we
hypothesized that TGFβ could similarly regulate lncRNAs that control EMT-associated
phenotypes. To address this, we treated NMuMG cells with vehicle or TGFβ (5 ng/ml)
for 24 hours to induce EMT (Fig 8A). Total RNA was labeled with digoxigenin and
hybridized to NCode Mouse Noncoding RNA Microarray. This is a high density oligo
array that contains lncRNAs and protein coding genes in order to study the dynamic
expression of a large subset of lncRNAs and associated protein coding genes within the
same biological sample. This array contains 2 replicates for each gene per sample to
ensure signal is consistent and reliable. We have plotted relative intensity signals of
replicate spots for lncRNAs in control cell and TGFβ-induced EMT to assess the
consistency of signal for lncRNA within given sample. Linear regression analysis shows
significance for both vehicle and TGFβ treated replicates indicating that signal within our
samples is consistent (Fig 8B-C). The microarray contains replicates for 10,802
lncRNAs in which signal was normalized, averaged, and plotted to assess overall
changes in expression in vehicle versus TGFβ induced EMT (Fig 8D).
We determined that lncRNA expression was significantly changed if average
signal of replicates changed ≥2-fold from vehicle to TGFβ treated samples (Fig 9A).
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Figure 8. LncRNA expression profile of TGFβ-induced EMT in NMuMG cells. (A)
TGFβ induces cell morphological change of EMT in NMuMG cells. The cells were
treated with vehicle (left) or 5 ng/ml TGFβ (right) for 24 hours and then photographed.
(B - C) Linear regression analysis of lncRNAs in 2 replicates after vehicle (B) and TGFβ
(C) treatment of NMuMG cells for 24 hours. (D) Scatter plot analysis comparing all
lncRNA changes vehicle vs. TGFβ-treated NMuMG. Note: red and green dots
represent up-regulated and down-regulated lncRNAs, respectively.

Using ≥2-fold change as criteria, 633 lncRNAs were down-regulated and 680 lncRNAs
were up-regulated following TGFβ-induced EMT (Fig 9B). Furthermore, we confirmed
the expression of several top changed lncRNAs by real-time PCR (Fig 9C-D). Tables 3
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and 4 summarize top 15 up-regulated and 15 down-regulated lncRNAs. (Tables 3 and
4).

Figure 9. Verification of TGFβ-regulated lncRNAs. (A) Heatmap and (B) diagram
representations of dysregulated lncRNAs between vehicle- and TGFβ-treated NMuMG
cells. (C) Real-time PCR analysis of representative TGFβ-upregulated and (D)
downregulated lncRNAs.
In 25,179 mRNAs represented on the chip, signal for each probe was averaged
and plotted to assess overall changes in EMT response (Fig 10A). Genes were
considered significantly changed if average fold change was greater than 2-fold. In total,
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1,096 genes increased and 2,220 decreased expression upon TGFβ-induced EMT (Fig
10B). Further RT-qPCR validation showed significant changes of several top scoring
and established typical TGFβ target genes including Col1a1, Ctgf, Itga5, Serpine1,
Kif12, Rbp4, ect., indicating that the lncRNA and mRNA data generated in this study are
dependable (Fig 10 C-D).

Strategy used to discover conserved human ortholog lncRNAs. In total, 680
lncRNAs were up-regulated 2-fold or greater. The ultimate goal of this project is to
identify lncRNAs important in driving human cancer development and/or metastasis.
Therefore from the data generated using the mouse lncRNA microarray, we developed
a strategy to predict mouse lncRNAs with a strong potential to have a conserved human
ortholog. To do this, we designed a workflow to which we subjected significantly TGFβinduced mouse lncRNAs (Figure 11). These mouse lncRNAs had to fit 4 criteria or be
thrown out. If all 4 criteria were met, we considered these transcripts strong candidates
to be conserved in human and potentially across other species. In this study, we
focused on transcripts induced and not repressed (Figure 11), as these genes could be
knocked down for functional analysis in both mouse and human. These 4 criteria are:

1.

Mouse lncRNA was induced by TGFβ >2-fold in NMuMG by follow up RTqPCR validation. This criterion served to validate the array and eliminate false
positive data points which may have been introduced during statistical analysis.
This also confirmed that the mouse lncRNA is regulated by an established
signaling pathway (TGFβ pathway) and associated transcription factors. Due to
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the high conservation of lncRNA promoter elements, lncRNAs are more likely to
be functional if they are regulated by established transcription factors which are
tightly regulated in the cell.
2.

Mouse lncRNA has significant sequence identity to human. Mouse lncRNA
sequence was used as query and BLAST analysis (blast.ncbi.nlm.nih.gov/
Blast.cgi) was performed against human genome (all assemblies) with a “semidiscontiguous” cutoff. The BLAST was against the genome because using this
strategy we were likely going to identify novel regions within the human DNA that
contained sequence similarity, however did not contain an annotated gene.
Currently, there are only about 3,991 lncRNAs annotated in NCBI database [148].
Also, a “semi-discontiguous” cutoff was used because it was unlikely there would
be exact sequence identity across the entire length of the gene, but rather many
short or some long stretches of high complementarity. In relation to the query, we
refer to the length of the stretch as “coverage”, and the amount of sequence
similarity as “identity”.

3.

The BLAST query must locate at syntenic loci in human genome. Strong
sequence coverage and identity that also locates at syntenic loci in human
genomes provide strong evidence that this lncRNA has been retained through
selective pressures of evolution. It is also important to check if this same
sequence identity locates at syntenic loci across species, this will further support
the argument for evolutionary conservation. If the BLAST sequence does not
map to syntenic loci, this could be due to redundancies and repeat elements
within the genome that may be transposable elements. Although these regions
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(i.e. Alu repeats and SINEs) may be functional in their own right, this study
focuses to characterize lncRNA genes and not transposable elements.
4.

Mouse lncRNA and identified genomic location in human can not overlap
with a protein coding gene. This is to eliminate doubt that this lncRNA is not
actually a conserved region within a protein coding gene; i.e. exonic, intronic, and
untranslated regions (UTRs). Proteins retain high sequence similarity across
species. It is important that the mouse and putative human ortholog are free
standing and intergenic, to eliminate any doubt that lncRNA is associated with a
protein coding transcript. There are examples of functional antisense and sense
lncRNAs that reside within and overlap with protein coding mRNAs, however
these were not considered in this study.

Test for expression of predicted human ortholog transcript. We have
selected the top 200 TGFβ-induced mouse lncRNAs identified in microarray to be
further analyzed using the 4 criteria described above. Using this strategy only 10 of the
200 mouse lncRNAs met all 4 criteria. Using the largest stretch of known conserved
sequence region in human, real-time PCR (RT-qPCR) primers were designed within this
region to detect presence of a transcript in human cells and its regulation by TGFβ. To
test this, we treated the primary human mammary epithelial cell, HMEC, with vehicle or
TGFβ for 24 hours and performed RT-qPCR. The aim of this strategy would be to
predict orthologs that are co-regulated by TGFβ in mouse and human, and provide an
avenue to demonstrate primers designed were on target. We can further validate this
through use of siRNAs.
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Figure 10. Dysregulated mRNAs in TGFβ-induced EMT. (A) Scatter plot analysis
comparing all mRNA changes vehicle vs. TGFβ-treated NMuMG cells (red and green
dots represent up-regulated and down-regulated mRNAs, respectively). (B) Diagram
summarizing number genes changed.
(C & D) Real-time PCR analysis of
representative TGFβ down-regulated (C) and up-regulated (D) mRNAs. Asterisks
represent p<0.05.
The stretches of similarity (“coverage”) typically ranged from ~100nt to 1kb, and
therefore designing RT-qPCR primers for a 100-150 base amplicon was not a problem.
It is also important to note that all samples were DNase treated prior to reverse
transcription step to eliminate genomic contamination and signal during PCR step.
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Interestingly, we observed that 3 of the 10 predicted human lncRNA orthologs were also
induced greater than 2-fold by TGFβ in HMEC (Fig 12A).

Figure 11. Schematic representation and workflow for identifying conserved
human orthologs. Each significantly up-regulated lncRNA in microarray was subjected
to 4 criteria. If all criteria were met, RTqPCR primers were designed for human lncRNA
to check changes in expression in TGFβ-treated HMEC cells.

The 3 mouse lncRNAs that have a human ortholog also regulated by TGFβ are
AK578, BB049, and AK060. Interestingly, BB049 maps to annotated human lncRNA
46

WDFY3-AS2. In addition, although human ortholog of AK562 was not induced greater
than 2-fold by TGFβ in HMEC, we were still interested in this transcript given its
genomic location within the 5-prime distal region of the HOXA locus. Several conserved
and functional lncRNAs have been shown to reside in HOX gene clusters, and therefore
we did not want to rule out the possibility that a functional lncRNA locates at this
location [48, 149, 150]. We next checked several established breast cancer cell lines for
expression of each of the 4 conserved lncRNAs. Interestingly, all 4 human orthologs
were over expressed in human breast cancer cell lines by RT-qPCR in comparison to
HMEC control, and each had a unique expression pattern (Fig 12B).

Human AK578 is over-expressed in human breast cancer patient. To provide
a proof of concept for how we settled on these 4 candidates, we will retrospectively
discuss AK578. Given the fact that if mouse AK578 is (1) regulated by TGFβ, (2) shares
significant sequence identity with human, (3) maps to syntenic loci, and (4) this region
does not overlap with any protein coding genes, we hypothesized that there was a
strong chance a human ortholog existed.
Mouse AK578 is ~2.8 kb transcript that locates on mouse chromosome 13 and
resides in an intergenic region with no overlap with protein coding genes. AK578 was
BLAST-ed to the human genome on “semi-discontiguous” cutoff, and this showed that
human genome contains a conserved region at syntenic loci in chromosome 5q14 (Fig
13A). This region of the genome is conserved in human with 68% “coverage” and 85%
“identity” to mouse AK578. This genomic region, to varying degrees, is conserved
across several other species, including chimpanzee, rat, bull, and even zebrafish (Fig

47

13B), suggesting that this region has been selected through evolutionary pressures and
contains a functional element.

Figure 12. Ortholog lncRNAs are regulated by TGFβ and overexpressed in breast
cancer cell lines. (A) Basal level expression was detected for all 10 predicted orthologs,
including 3 were regulated by TFGβ in HMEC (*). A fourth ortholog remained of interest
due to the fact that it’s genomic location in the very well conserved HOXA locus (#). (B)
All 4 human orthologs show elevated expression across a panel of established breast
cancer cell lines in comparison to normal cell HMEC.

RT-qPCR primers were designed for mouse and human AK578. NMuMG and
HMEC cells were treated with TGFβ (5 ng/ml) for 24 hours and subsequently assessed
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for AK578 expression. As indicated in microarray analysis, mouse AK578 was validated
as being induced by TGFβ >2.5-fold. Interestingly, we were able to detect ~3-fold
induction of a human ortholog when using qPCR primers designed within conserved
human region (Fig 13C). These data suggest that a conserved human transcript
regulated by TGFβ does exist and our strategy was successful. We also obtained
human patient breast normal and tumor RNAs from Moffitt Cancer Center Tissue Core
to assess expression of human AK578. We performed semi-quantitative qPCR (semiqPCR) and observed significant elevated expression of AK578 in patient breast tumor
(T) compared to normal control (N) RNA samples (Fig 13D). This result suggests that
AK578 expression is relevant in human and may functionally contribute to breast cancer
development and metastasis.
The following chapters will discuss functional characterization and mechanisms
of the other 3 mouse and human ortholog candidates AK562, BB049, and AK060.

Methods

LncRNA Microarray. NCode™ Mouse Noncoding Microarray chip from Life
Technologies (Carlsbad, CA, USA), which contains 10,802 lncRNAs and 25,178
protein-coding genes, was used to interrogate lncRNA and mRNA changes in vehicleversus TGFβ-treated (5 ng/ml) NMuMG cells after 24 hours. TGFβ was purchased from
R&D Systems (Minneapolis, MN, USA). Total RNA was end labeled, and hybridized to
the array. Hybridization and analysis were performed in MicroArray Core at H. Lee
Moffitt Cancer Center.
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RNA isolation and RT- and semi- qPCR polymerase chain reaction. Total
RNAs were isolated with Trizol reagent following manufacturer’s protocol (Life
Technologies and then subjected to RT reaction using High Capacity cDNA Reverse
Transcription Kit (Life Technologies, Carlsbad, CA, USA). The RT product was used for
subsequent qPCR. The qPCR was performed with SYBR Green 2x Master Mix (Life
Technologies Carlsbad, CA, USA) on ABI HT9600 from Applied Biosystems (Foster City,
CA, USA) and the data were collected and analyzed using ABI SDS version 2.3. ∆CTs
were normalized to GAPDH, and ∆∆CT analysis was performed to calculate relative
RNA expression.
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Figure 13. Mouse AK578 has human ortholog transcript and is up-regulated in
patient breast tumor. (A) Mouse AK578 and AK578 (h) locate at syntenic loci are
intergenic sharing no overlap with protein coding gene. (B) Mouse AK578 is very well
conserved across several species in sequence identity and coverage including
zebrafish (Danio rerio). (C) AK578 (h) has elevated expression in 16 human breast
tumor RNAs examined in comparison to 8 normal breast controls.

51

Table 3. Top up-regulated lncRNAs following TGFβ-induced EMT in NMuMG.
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Table 4. Top down-regulated lncRNAs in TGFβ-induced EMT in NMuMG.
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CHAPTER 3
LncRNA-HIT mediates TGFβ-induced EMT in mammary epithelia and associates
with metastasis and poorer overall patient survival

Introduction

The Homeobox genes (Hox genes) are well-conserved across several species
and encode for a cluster of transcription factors important in development [151]. In
mouse, human, and other vertabrates, the Hox genes are organized into 4 groups;
Hoxa, Hoxb, Hoxc, and Hoxd. These genes are spatially and temporally expressed
during embryogenesis and development to ensure proper segmentation and bilateral
symmetry across the body axis [152]. For this reason, the expression of the Hox genes
is very tightly regulated by several factors, as disruption can result in major
developmental complications [153]. It has now become apparent that in malignancies
such as cancer, Hox genes can become dysregulated and drive tumorigenesis and
metastasis. It has also been suggested that Hox gene expression is partly governed by
locally residing lncRNAs that can act in “cis” or in “trans” [48, 149].
In this Chapter, we identified mouse AK562 to be an uncharacterized lncRNA
which is located in Hoxa gene cluster and significantly up-regulated in the lncRNA
microarray. AK562 resides downstream in the sense direction but not overlapping with
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Hoxa13 that was significantly Induced by TGFβ, and thus was named lncRNA-HIT.
Depletion of lncRNA-HIT inhibits TGFβ induced migration, invasion, and EMT in both
NMuMG and 4T1 cells. LncRNA-HIT is well conserved in sequence and chromosomal
location from mouse to human. We were able to detect lncRNA-HIT in human and
observed that increased expression directly correlates with breast cancer progression.
Furthermore, we showed that human lncRNA-HIT can drive breast cancer by positively
regulating HOXA13. The following discusses mouse and human ortholog, lncRNA-HIT.

Results

LncRNA-HIT mediates TGFβ-induced invasion, migration, and EMT in
NMuMG cell. LncRNA-HIT is one of the top TGFβ up-regulated lncRNAs, and was of
particular interest to us given its genomic location i.e., within the homeobox domain A
(HOXA) gene cluster.

LncRNA-HIT resides in the sense orientation to the HOXA

protein genes and downstream of HOXA13. There is no overlap between these
transcripts and a gap of ~1.4 kb between the HOXA13 3-prime termini and lncRNA-HIT
5-prime transcriptional start site (Fig 14A). Previous studies have shown that the HOX
gene clusters (HOXA, HOXB, HOXC, and HOXD) are very well conserved across
species and several lncRNAs have been shown to be functionally important within these
regions [48, 149, 150].
Consistent with the microarray finding, RT-qPCR analysis showed that lncRNAHIT expression was induced by TGFβ (Fig 14B). LncRNAs have been shown to play
functional roles in both the nuclear and cytoplasmic compartments [56, 154-156].
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Therefore, we performed cellular fractionation after 24 hours of treatment with TGFβ to
assess the subcellular localization of lncRNA-HIT. We observed that lncRNA-HIT
expression was induced and localized to the nucleus upon TGFβ treatment (Fig 14C),
suggesting that lncRNA-HIT functions in the nucleus.

Figure 14. LncRNA-HIT locates in Hoxa gene cluster and is induced by TGFβ. (A)
Diagram shows lncRNA-HIT location. (B) RT-qPCR revealed that lncRNA-HIT is
induced in NMuMG cells after TGFβ treatment for 24 hours. (C) lncRNA-HIT is
predominantly localized in the nucleus. Following treatment with vehicle or TGFβ for 24
hours, NMuMG cells were fractionated and then subjected to semi-quantitative PCR
(top), and semi-quantitative PCR with control primers (medium and bottom).

LncRNA-HIT mediates TGFβ-induced motility and EMT. We further designed
2 siRNAs against lncRNA-HIT (si-HIT-1 and si-HIT-2) to experimentally address its
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functional significance in TGFβ-induced migration, invasion and EMT. NMuMG cells
were transfected with scrambled control siRNA (si-CTL), si-HIT-1, or si-HIT-2 for 48
hours. Cells were then treated with TGFβ (5 ng/ml) or vehicle control for 24 hours.
Following confirmation of knockdown of lncRNA-HIT (Fig 15A), we performed twochamber migration and invasion assays and found that depletion of lncRNA-HIT
significantly inhibited TGFβ-induced migration and invasion compared to si-CTL (Fig
15B-C).
TGFβ-induced EMT in NMuMG causes the cell to move from an epithelial to a
more mesenchymal and fibroblast-like gene signature. A hallmark of EMT is the loss of
E-cadherin and increase of Vimentin expression. To test whether depletion of lncRNAHIT can abrogate TGFβ-induced EMT, we transfected the cells for 48 h with si-CTL, siHIT-1, and si-HIT-2 and then treated cells with and without TGFβ for 24 h to induce
EMT. Immunoblotting analysis revealed that TGFβ treatment reduced E-cadherin and
increased Vimentin in si-CTL cells.

However, knockdown of lncRNA-HIT largely

overrode TGFβ action in E-cadherin and Vimentin expression (Fig 15D). This result was
recapitulated using immunofluorescence staining to visualize expression of E-cadherin
and Vimentin (Fig 15E).

We noted that TGFβ-disrupted tight junctions were largely

restored by knockdown of lncRNA-HIT.

Ectopic expression lncRNA-HIT increases cell motility and EMT. Moreover,
we examined the effects of overexpression of lncRNA-HIT alone on EMT in NMuMG
cells. Following transfection of lncRNA-HIT into NMuMG cells (Fig 16A), we observed a
significant increase in both migration and invasion (Fig 16B-C). Ectopic
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Figure 15. LncRNA-HIT mediates TGFβ-induced cell migration, invasion and EMT.
(A) NMuMG cells were transfected with indicated siRNAs. After treatment with vehicle
or TGFβ for 48 hours, RNAs were isolated and analyzed for lncRNA-HIT expression
using real-time PCR. (B-C) Depletion of lncRNA-HIT reduces TGFβ-triggered cell
migration and invasion. LncRNA-HIT knockdown and control NMuMG cells were
seeded in Boyden chamber without (B) and with (C) matrigel to assess changes in
migration and invasion. (D-E) Knockdown of lncRNA-HIT abrogates a hallmark change
of EMT induced by TGFβ. NMuMG cells were transfected with indicated siRNAs. After
48 hours of transfection, the cells were left untreated or treated with TGFβ for 16 hours.
Expression of E-cadherin and Vimentin were assessed by Western blot (D).
Immunofluorescence staining was also performed with antibodies against E-cadherin
and Vimentin (E). Note: TGFβ-induced tight-junction dissolution was largely rescued by
depletion of lncRNA-HIT. Asterisks represent p<0.05.

expression of lncRNA-HIT was also able to disrupt tight junction as indicated by Ecadherin immunofluorescence staining (Fig 16D). Collectively, these data indicate that
lncRNA-HIT plays a pivotal role in TGFβ-induced cell migration, invasion, and EMT.
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Figure 16. Over-expression of lncRNA-HIT promotes migration, invasion and
disrupts tight junction. (A) LncRNA-HIT was ectopically expressed in NMuMG cells
for 48 hours. Cells were then seeded in the upper Boyden Chamber without (B) and
with (C) matrigel to determine changes in migration and invasion. (D) Presence of tight
junction following overexpression of lncRNA-HIT was assessed using E-cadherin
antibody for immunofluorescence staining.
LncRNA-HIT is up-regulated in 4T1 cells and its depletion inhibits cell
migration, invasion, lung metastasis and tumor growth. We further examined
lncRNA-HIT expression in four well-characterized mouse mammary tumor cell lines
(67NR, 168FARN, 4TO7 and 4T1) derived from a single spontaneously arising
mammary tumor in a BALB/c mouse. Although each of these tumor cell lines is able to
form primary tumors, they have different metastatic properties. 67NR cells form primary
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tumors readily, but tumor cells do not intravasate. 168FARN cells can be detected in
lymph nodes but rarely in other tissues, suggesting that they can enter the vasculature,
but extravasate inefficiently. 4TO7 cells can disseminate from primary mammary tumors
into the lungs but don't form visible lung nodules. Moreover, disseminated 4TO7 cells in
the lungs rapidly disappear when the primary tumor is removed, suggesting that they
are unable to colonize in distant sites. 4T1 cells are fully metastatic and form
macroscopic lung nodules from primary mammary tumors. Interestingly, lncRNA-HIT
was significantly elevated in the 4T1 cell and expressed at low levels in other 3 cell lines
(Fig 17A), suggesting that lncRNA-HIT may be involved in breast cancer metastasis.
The importance of lncRNA-HIT in 4T1 cell migration and invasion was further
investigated. After cells were transfected with si-HIT-1, and si-HIT-2 as well as si-CTL
for 48 h (Fig 17B), two-chamber migration and invasion assays were performed as
described above. After 16 hours, we observed a significant reduction in both migration
and invasion of 4T1 cells in which lncRNA-HIT was depleted (Fig 17C-D). However, we
did not observe that TGFβ induced lncRNA-HIT in 4T1 cells and that knockdown of
lncRNA-HIT had no effect on TGFβ-induced 4T1 cell migration and invasion (data not
shown).
We next examined the effect of lncRNA-HIT on anchorage independent growth in
soft agar following depletion of lncRNA-HIT. Compared to si-CTL treated 4T1 cells, siHIT-1 and -2 transfected cells resuspended in soft agar and cultured for 2 weeks
showed markedly reduced colony formation capacity (Fig 17E). Notably, the orthotopic
breast cancer model revealed that knockdown of lncRNA-HIT dramatically inhibited
number of metastatic lung nodules, breast tumor volume, and tumor weight (Fig 17F-H).
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Identification of E-cadherin as a major target of lncRNA-HIT. To identify the
genes regulated by lncRNA-HIT, we performed Affymetrix gene expression analysis
after 48 h ectopic expression of lncRNA-HIT in NMuMG (Fig 18A). One of the significant
deregulated genes that are associated with EMT was E-cadherin. Accumulating studies
have shown that loss of E-cadherin is not only a hallmark of EMT but also a key driver
of EMT and metastasis [157-160]. Thus, we further examined if lncRNA-HIT inhibits Ecadherin transcription by performing RT-qPCR and using E-cadherin luciferase
promoter assay. Following ectopic expression of lncRNA-HIT, we observed a significant
loss of E-cadherin mRNA and promoter activity (Fig 18B-C). Furthermore, this
correlated with a loss of E-cadherin protein after 72 h overexpression of lncRNA-HIT
(Fig 5D), however we did not see changes of other EMT-associated genes ZEB1 or
Snail at this time point. Further, the effects of lncRNA-HIT induced EMT, migration, and
invasion were rescued through introduction of ectopic E-cadherin (Fig 18E-G).

LncRNA-HIT is conserved across several species. In “BLAST-ing” mouse
lncRNA-HIT to the human genome, we found a significant conservation at syntenic
locus in human chromosome 7p15 located downstream of HOXA13 in sense direction
(Fig 19A), suggesting that lncRNA-HIT was retained through evolutionary pressures.
The conservation from mouse to human genomic sequence is 79% identity across 99%
coverage. Interestingly, lncRNA-HIT is well conserved in several other higher organisms
at the DNA level. (Fig 19B). Furthermore, to check for evidence and expression at the
RNA level in human, we “BLAST-ed” the human genomic DNA sequence to the
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expressed sequence tag bank (ESTs). This result showed several reported transcripts
residing within this region and thus lncRNA-HIT expression at the RNA level (Fig 19C).

Figure 17. LncRNA-HIT is elevated in metastatic 4T1 cells and its knockdown
results in significant reduction of cell migration, invasion, and metastasis. (A)
Expression of lncRNA-HIT was evaluated in 4 isogenic mouse breast cancer cell lines
67NR, 168FARN, 4T07 and 4T1 by semi-quantitative RT-PCR. (B) Knockdown of
lncRNA-HIT with 2 siRNAs in 4T1 cells. Cells were transfected with indicated siRNAs
and then analyzed lncRNA-HIT expression by RT-qPCR. (C and D) Depletion of
lncRNA-HIT dramatically reduces 4T1 cell migration and invasion. Following treatment
with indicated siRNAs, 4T1 cells were assayed for cell migration and invasion. (E) Soft
agar colony formation assay was performed after 4T1 cells were transfected with si-CTL,
si-HIT-1, or si-HIT-2. Colony forming capactity was dramatically decreased after 2
weeks in lncRNA-HIT depleted cells. (F) Orthotopic breast cancer model. Control and
lncRNA-HIT knockdown 4T1 cells (4 x 106) were injected to mammary fat pad of female
nude mice and tumor growth was monitored for 4 weeks. Number of metastatic lung
nodules (F), tumor volume (G), and tumor weight (H) were assessed at completion of
experiment. Asterisks represent p<0.05.
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Figure 18. E-cadherin is a target of lncRNA-HIT. (A) Affymetrix Gene Expression
Analysis was performed on NMuMG cells transfected with vector and lncRNA-HIT. (B)
RT-qPCR was performed to confirm a loss of E-cadherin expression. (C) PGL3-Ecadherin promoter was co-transfected with vector or lncRNA-HIT into NMuMG cell for
48 hours and assayed for luciferase activity. (D) After 72 h overexpression of lncRNAHIT, expression of E-cadherin, ZEB1 and Snail were examined by immunoblot with
indicated antibodies. (E-G) After 72 hours transfection, ectopic expression of E-cadherin
was able to rescue lncRNA-HIT effects on loss of tight junction (E), migration (F) and
invasion (G). Asterisks represent p<0.05
LncRNA-HIT is elevated in human breast cancer cell lines and knockdown
reduces migration and invasion. Since we observed that lncRNA-HIT is conserved in
human genome and several ESTs reside in this location, we designed PCR primers and
siRNAs within this region to test for expression and knockdown. We performed semi-
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Figure 19. LncRNA-HIT is conserved in across several species and human ESTs
have been reported. (A) Mouse lncRNA-HIT was “BLAST-ed” to human genomic DNA,
and results show significant similarity and coverage at snytenic loci in human
chromosome 7p15. (B) LncRNA-HIT is well conserved in several species at genomic
DNA level. (C) In “BLAST-ing” human genomic sequence corresponding to lncRNA-HIT
to the EST database, several RNA transcripts have been reported in this location.
quantitative PCR (semi-qPCR) in a panel of established breast cancer cell lines and
observed up-regulation of lncRNA-HIT in several including MD-AMB-231, HS578T,
BT474, MD-AMB-361, and T47D (Fig 20A). In the highly metastatic MD-AMB-231 we
were able to knockdown lncRNA-HIT to 0.32-fold and 0.39-fold expression respectively
using si-hHIT-1 and si-hHIT-2 in comparison to control siRNA (si-CTL) (Fig 20B). After
knockdown of lncRNA-HIT for 48 h, cells were seeded in upper Boyden Chambers and
assayed for changes in migration and invasion (matrigel coated). Both si-hHIT-1 and -2
resulted in significantly reduced migration and invasion after 16 h (Fig 20C-D).
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Depletion of lncRNA-HIT decreases primary tumor growth and metastasis
in vivo. Given that we were able to reduce 4T1 cell tumor growth and lung metastasis
(Figure 17) and human breast cancer cell migration and invasion in vitro setting (Figure
20), we next investigated whether knockdown of lncRNA-HIT could reduce cancer
phenotypes in vivo in human breast cancer cells. To do this, we employed a mouse
orthotopic xenograft model using stable expressing luciferase MD-AMB-231 in

Figure 20. Human lncRNA-HIT is over-expressed in several breast cancer cells
lines and depletion of lncRNA-HIT results in reduced migration and invasion. (A)
Semi-qPCR was performed in a panel of breast cancer cell lines for expression of
lncRNA-HIT. (B) Knockdown of lncRNA-HIT was confirmed by RT-qPCR in MD-AMB231. After 48 h post-knockdown, cells were assayed for migration (C) and invasion (D).
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NOD/Scid gamma (NSG) mice. NSG mice are advantageous in orthotopic cancer
models due to germline SCID mutation in the Prkdc gene and an additional targeted
mutation in the IL2RG gene (IL2 receptor) [161, 162]. The Prkdc mutation results in
mutation of DNA-PK gene product that can no longer function in DNA repair process.
This results in B and T lymphocytes being able to successfully undergo V-D-J
recombination and therefore can not express function B and T receptors. The IL2
receptor is critical for natural killer cell (NKT) function and this mutation will disrupt the
ability of IL2R to recognize the IL2 ligand. Therefore, the NSG mice have no adaptive
immunity and a severely impaired innate immunity. These deficiencies allow for
reproducible xenografts of human cancer cells, as well as more reliable metastasis
models including breast cancer [163].
MD-AMB-231-Luciferase cells were transfected with si-CTL or si-HIT-1 for 48
hours and then washed in PBS and trypsinized. Cells were then spun at low speed and
resuspended in PBS at a concentration of 4 x 106 cells per 100 ul. Four NSG mice from
each group received injection in the lower mammary fat pad. Tumors were established
and tracked over the course of 7 weeks. Similar to mouse 4T1 cells, knockdown of
lncRNA-HIT in MDA-MB-231 had significantly slowed tumor growth and volume (mm3)
as measured by standard caliper measurements and as quantified by luciferase activity
using Xenogen Bioluminescent Imaging System and Software (Fig 21A-C). At the
endpoint week 7, there was also significantly more decreased luciferase activity in the
lung in lncRNA-HIT knockdown cell compared to si-CTL (Fig 21D-E). Further,
hematoxylin and eosin (H & E) staining revealed less lung nodules in si-HIT group (Fig
21F).
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LncRNA-HIT regulates 5-prime distal HOXA genes including HOXA13. A
previous report has shown that HOTTIP, a distal 5-prime residing lncRNA, can
positively regulate locally residing genes like HOXA13 and HOXA11 through recruitment
of the WDR5/MLL1 chromatin remodeling complex [149]. Since lncRNA-HIT also
resides in this region we hypothesized that it also may regulate genes within HOXA
cluster. To test this, we transfected MD-AMB-231 cell line with si-CTL and si-HIT-1 for

Figure 21. NSG mouse orthotopic model of control versus depleted lncRNA-HIT.
(A-C) MD-AMB-231-Luciferase cells were transfected with control (si-CTL) or si-HIT-1
for 48 h, washed, trypsinized, and 4 x 106 cells were injected into lower fat pad at day 0.
Tumor volume (mm3) was tracked and quantified via standard caliper measurements
(A) and bioluminescent imaging (B & C). Image is representative of primary tumor at
week 3 post injection. (D-E) Just prior to sacrificing, lungs were imaged and quantified
for luciferase activity. (F) After sacrificing lungs were removed, paraffin embedded, and
H & E stained to visualize metastasis. Asterisks represents p<0.05.
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48 h, isolated total RNA, and performed RT-qPCR for expression of genes in this cluster.
Interestingly we found a similar pattern in that depletion of lncRNA-HIT resulted in
decreased RNA expression of HOTTIP, HOXA13, and HOXA11 (Fig 22A). However we
observed no significant change in HOXA10, HOXA9, and HOXA7. This suggests
lncRNA-HIT is “cis” acting and can positively regulate genes in close proximity. The loss
of HOXA13 was also evident at the protein level (Fig 22B).

Figure 22 LncRNA-HIT knockdown results in decreased mRNA expression
neighboring genes. (A) MD-AMB-231 was transfected with si-CTL or si-hHIT-1 for 48 h,
total RNA was isolated. RT-qPCR analysis was performed on a panel of genes within
HOXA locus. (B) Similarly transfected cell were lysed and assayed for HOXA13
expression. Asterisks represents p<0.05.

HOXA13 is important in driving breast cancer migration and invasion. It has
previously been reported that HOXA13 can be cancer promoting and indicator of poorer
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patient survival in esophageal squamous carcinoma and hepatocellular carcinoma [164,
165]. Since lncRNA-HIT regulates HOXA13 mRNA and protein, we aimed to assess if
phenotypic changes are associated with loss of HOXA13 gene product. We transfected
MD-AMB-231 cells with siRNA against HOXA13 (si-HOXA13). We observed almost
complete loss of mRNA as measured by semi-qPCR after 48 h knockdown (Figure 23A).
MD-AMB-231 is a triple-negative highly metastatic cell line that phenotypically looks
very mesenchymal-like. Interestingly, MD-AMB-231 cells transfected with si-HOXA13
seem to dramatically revert a more rounded, epithelial-like cell shape and state (Figure
23B). The significance of this phenotypic change at the molecular level warrants further
research. Loss of HOXA13 also resulted in significantly impaired migration and invasion
(Figure 23C and 23D).

LncRNA-HIT is elevated in patient invasive ductal carcinoma, high grade
tumor, positive lymph node, and associates with poorer patient survival. We
asked if the expression of lncRNA-HIT associated with cancer invasiveness in human
primary breast carcinoma. A total of 89 breast cancer specimens (15 noninvasive and
74 invasive breast carcinomas) and 4 normal and 9 hyperplasia breast tissue samples
were examined for the expression of lncRNA-HIT. Locked nucleic acid in situ
hybridization (LNA-ISH) analyses revealed high levels of lncRNA-HIT in 29 of 74
invasive tumors but in only 2 of 15 noninvasive cancer tissues (Fig 24A). The level of
expression of lncRNA-HIT in normal breast tissue was low and gradually increased to
invasive carcinoma, suggesting lncRNA-HIT may play a role in breast tumor
progression (Fig 24B). These data further support the findings demonstrating the
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involvement of lncRNA-HIT in EMT and invasion as we previously observed in NMuMG
and 4T1 cells, and suggest that conserved human lncRNA-HIT could play a pivotal role
in breast cancer metastasis.

Figure 23. HOXA13 depletion changes cell morphology and results in decreased
migration and invasion. (A) MD-AMB-231 cells were transfected with si-CTL or siHOXA13 for 48 hours and mRNA changes were measured by semi-qPCR. (B)
Depleting HOXA13 results in a change in MD-AMB-231 cell morphology from a
mesenchymal-like to a more epithelial-like state. Loss of HOXA13 also resulted in
decreased cell migration (C) and invasion (D). Asterisks represents p<0.05.
We performed additional TMA-ISH to evaluate if there is clinical or pathological
relevance in patients with higher expression of lncRNA-HIT. Indeed, elevated levels of
lncRNA-HIT correlated with poorly differentiated late-grade breast tumor (p = 0.0036)
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Figure 24. Elevated levels of lncRNA-HIT associates with invasive breast cancer
in human, late grade tumor, positive lymph node, and poorer overall patient
survival. (A) Locked nucleic acid in situ hybridization (LNA-ISH). LNA-oligonucleotide
of lncRNA-HIT was labeled with digoxigenin-ddUTP using the Dig-5’-end labeling kit
and hybridized to a human breast cancer TMA. Signal was measured using Allred Scale.
(B) Representative photomicrographs of sections of a normal, hyperplasia, noninvasive and invasive breast tumor tissues are shown. (C and D) Summary of clinical
and pathological characteristics associated with elevated lncRNA-HIT expression. (D)
Kaplan-meier curve was plotted to assess overall patient survival in IDC patients with
high and low expression of lncRNA-HIT. Asterisks represent p<0.05.
and positive lymph node (p < 0.0001) (Fig 24C). It is interesting to note that although not
significant, high levels of lncRNA-HIT closely associate with triple-negative breast
cancer subtype as MD-AMB-231 cell line. Of importance, elevated lncRNA-HIT
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associates with poorer overall patient survival (p = 0.046) (Fig 24D). This result strongly
suggests that lncRNA-HIT may play a functional role in patient mortality by driving EMTassociated phenotypes and metastasis in human cancer.

Discussion

Accumulating studies have demonstrated that TGFβ pathway plays a critical role
in breast cancer metastasis as the roles of several protein coding genes and miRNAs
have been described in this process [166-169].

In this study, we report lncRNA

expression signature of TGFβ-induced EMT in mouse mammary gland epithelial
(NMuMG) cells. Over 600 lncRNAs were significantly up-regulated or down-regulated
during EMT, respectively.

Further, we showed that lncRNA-HIT, one of top up-

regulated lncRNA, plays an important role in TGFβ-induced EMT, cell migration, and
invasion. Depletion of lncRNA-HIT can reverse the process of EMT associated gene
expression of E-cadherin and vimentin. Furthermore, lncRNA-HIT expression is
significantly elevated in the highly metastatic cell lines 4T1 and MDA-MB-231.
Depletion of lncRNA-HIT results in significant reduction of both migration and invasion
as well as tumor growth and lung metastasis.

LncRNA-HIT is well conserved in

sequence and genomic location from mouse to human. Human lncRNA-HIT expression
is associated with more invasive tumor and breast cancer progression. These findings
are important for several reasons.

First, this is the first study to provide lncRNA

expression signature of TGFβ-induced EMT in mouse mammary gland epithelial cells.
Second, this study established a critical role of a previously uncharacterized lncRNA,
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lncRNA-HIT, in TGFβ-induced EMT. Finally, conserved lncRNA-HIT was shown to be
an important lncRNA in mouse and human breast cancer progression.
LncRNA-HIT resides in the 5 prime distal HOXA gene cluster in between but not
overlapping with HOXA13 and HOXA11-AS. This region of the genome is highly
conserved across several species and several functional lncRNAs have demonstrated
to be important within the HOXA clusters, including neighboring HOTTIP and HOXA11AS [149, 170, 171]. HOTTIP has been shown to positively regulate the protein coding
genes in close proximity, notable HOXA13, through the recruitment of WDR5, a
component of the histone methyltransferase protein MLL complex that promotes
transcriptional activation [149]. It has also recently been reported that elevated levels of
human HOTTIP and HOXA13 expression associates with disease progression and
poorer survival in hepatocellular carcinoma. [165]. However, lncRNAs HOTTIP and
HOXA11-AS were not induced by TGFβ in our microarray analysis, suggesting lncRNAHIT has a unique role in TGFβ-induced EMT.
While microarray analysis revealed expression changes of a number of typical
TGFβ-regulated protein-coding genes upon TGFβ-induced EMT, the array didn’t show
altered expression of lncRNA-HIT neighbor genes including HOXA13 and HOXA11.
Further investigation is warranted to determine the exact mechanism and target genes
of lncRNA-HIT, as well as its use as a therapeutic target for breast cancer metastasis
intervention
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Methods

Plasmids and siRNAs. A 1,178nt insert of lncRNA-HIT was amplified and TAcloned into pGEM-T-easy vector from Promega (Madison, WI, USA) using NMuMG
genomic DNA template. Plasmid containing insert was sequenced, insert was then
isolated by EcoRI restriction digest, and cloned into pcDNA3.1 (pcDNA-HIT). SiRNAs
were designed using IDT siRNA Design Software and 2 best siRNAs against lncRNAHIT (si-HIT-1 and si-HIT-2) were determined empirically and used for experimentation.

Affymetrix Gene Expression Array. GeneChip Human Genome U133 Plus 2.0
Array was purchased from Affymetrix (Santa Clara, CA, USA). After 48 hours
transfection of pcDNA-HIT in NMuMG, total RNA was isolation from samples and
hybridized to array according to manufacturer’s protocol. Hybridization and analysis was
performed in MicroArray Core at H. Lee Moffitt Cancer Center.

Invasion and migration assays. NMuMG and 4T1 cell lines were transfected
with control siRNA (si-CTL), si-HIT-1 or -2. After transfection for 48 hours, NMuMG
cells were treated with TGFβ (5ng/ml) or vehicle control for 24 hours and then seeded
into the upper chamber of Boyden Chambers coated without (migration) and with
(invasion) Matrigel. Top chambers contained serum-free media while lower chambers
had media containing 10% fetal bovine serum. After 16 hours, invasion and migration
were evaluated and quantified by taking mean and standard deviations of 4 non-biased
image fields.
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Cell Lines, treatment, and tumor specimens. Cancer cell lines were obtained
from ATCC (Manassas, VA, USA) and grown according to recommended culture
conditions. Primary NMuMG and HMEC cell lines were maintained in Dulbecco’s
modified Eagle medium plus 10% fetal bovine serum and MEGM medium from Lonza
Inc. (Hopkinton, MA, USA) plus manufacturer’s supplements, respectively. Cells were
treated with TGFβ at a concentration of 5 ng/ml for times indicated. Cell transfections
were

performed

with

Lipofectamine

2000

(Life

Technologies)

according

to

manufacturer’s protocol. Frozen primary normal and tumor breast tissues were procured
anonymously from patients who underwent surgery at H. Lee Moffitt Cancer Center, and
approved by the institutional review board and in accord with an assurance filed with
and approved by the US Department of health and human services. Each tumor
contained at least 80% tumor cell as confirmed by microscopic examination. Tissues
were snap-frozen to avoid RNA degradation and RNA was isolated with Trizol. Breast
cancer tissue microarray (TMA) was obtained from Moffitt Cancer Center Tissue Core
and approved under institutional review board.

Immunofluorescence, immunoblotting, and antibodies. The cells were grown
to 60% confluence on cover slips and transfected with si-CTL, si-HIT-1 or -2 for 48
hours. Subsequently, TGFβ (5 ng/ml) was added to siRNA transfected cells for times
indicated in Figure Legends. Briefly, cells were washed with PBS, fixed with 10%
formalin containing methanol, and permeabilized with 1% NP-40 in PBS. Cells were
blocked in 10% normal goat serum for 1 hour, and 1:200 dilution of primary antibodies
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were incubated at 4oC overnight. Cover slips were washed in PBS 3 times and then
appropriate secondary antibodies were added at 1:500 dilution. Cover slips were
washed in TBS 3 times, counterstained with DAPI, and fixed for visualization.
Western blot was performed as previously described [172]. The band intensity of
Western blots was quantified using ImageJ Software and represented as ratio of target
gene/β-actin. Antibody against E-cadherin was purchased from BD Transduction Labs
(San Jose, CA, USA), Lamin A/C from Santa Cruz Biotechnology (Santa Cruz, CA,
USA), and antibodies for Vimentin and GAPDH from Cell Signaling Technologies
(Danvers, MA). Alexa Fluor secondary anti-mouse and anti-rabbit antibodies for
immunofluorescence were purchased from Life Technologies and HRP linked antibody
for Western blot analysis was purchased from Sigma (St. Louis, MO, USA).

Soft agar colony formation assay. 4T1 cells were transfected with si-CTL, siHIT-1 or -2 for 48 hours then washed, trypsinized, and resuspended in RPMI. A bottom
layer of 0.6% agar in RPMI was poured, and top layer of 0.3% agar in RPMI was placed
on top containing 1000 cells per 12-well and allowed to grow for 2 weeks. Four
replicates were plated for each condition and quantitation is represented as mean and
standard deviations of colonies counted in 4 non-biased fields.

Luciferase reporter assay. E-cadherin promoter luciferase plasmid was cotransfected with vector or pcDNA-HIT into NMuMG for 48 hours. Cells were then
washed in PBS, lysed, and then firefly substrate was added to detect expression of
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luciferase activity. The reaction was stopped using renilla substrate as a control and
performed using Promega Dual Luciferase Assay Kit (Madison, WI USA).

Orthotopic mouse breast cancer model. Stable luciferase expressing MDAMB-231 cell line was transfected with si-CTL or si-AS2-1 for 48 hours. Cells were
washed in PBS, trypsinzed, centrifuged, and resuspended in PBS at a concentration of
4 x 106 cells per 100ul. Six-week old NOD Scid gamma (NSG) mice were purchased
from Jackson Laboratories (Bar Harbor, ME, USA) and each mouse received 100ul
injection into lower mammary fat pad. Mice tumor volume and luminescence signal were
documented by injecting D-Luciferin K+ Salt Bioluminescent Substrate and imaged
using Xenogen IVIS Imaging System 200 (Waltham, MA, USA).

Locked nucleic acid in situ hybridization of formalin-fixed, paraffinembedded tissue microarray (LNA-TMA-ISH). LncRNA-HIT locked nucleic acid (LNA)
probe was prepared by 5 prime end labeling with digoxigenin-ddUTP terminal
transferase using the DIG 5 Prime End Labeling Kit from Roche (Indianapolis, IN, USA).
Following deparaffinization and proteinase K digestion, breast tumor TMAs were
prehybridized for 1 h and then hybridized with 10 nmol/L LNA lncRNA-HIT probe in a
hybridization buffer (Roche) for 12 h. After three consecutive washes in 4× SSC/50%
formamide, 2× SSC, and 0.1× SSC, sections were treated with a blocking buffer
(Roche) for 1 h and incubated with anti-DIG-AP Fab fragments (Roche) for 12 h.
Following wash for three times in 1× maleic acid and 0.3% Tween 20 buffer, reactions
were detected in a detection solution [100 mmol/L Tris-HCl (pH 9.5) and 100 mmol/L
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NaCl] in the presence of nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate
from Promega (Madison, WI, USA) and then visualized under a microscope.

78

CHAPTER 4
WDFY3-AS2 promotes breast cancer EMT, metastasis, and associates with poorer
patient survival and triple-negative breast cancer

Introduction

In the array, we also found mouse lncRNA, BB049, to be up-regulated in
response to TGFβ treatment. This transcript shares sequence and maps to human
ortholog, WDFY3-AS2. Interestingly, WDFY3-AS2 expression is also induced by TGFβ
in the primary human mammary epithelial cell line HMEC. WDFY3-AS2 expression is
elevated in human breast tumor and metastasis. Clinical and pathological analysis
revealed that high WDFY3-AS2 associates with poorer patient survival, high grade
tumor, positive lymph node metastasis, and triple-negative breast cancer subtype.
Knockdown and over-expression experiments demonstrate that WDFY3-AS2 can
regulate TGFβ induced EMT, migration, invasion, and proliferation. In vivo, loss of
WDFY3-AS2 resulted in slowed primary tumor growth and decreased lung metastasis in
mouse orthotopic xenograft model. Lastly, we have shown that WDFY3-AS2 functions
in “cis” to regulate WDFY3 and in “trans” to regulate STAT3 through protein binding
partner hnRNP-R.
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The WDFY3 gene product, also known as ALFY, is important in selective
macroautophagy, which can promote clearing of cargo by stimuli other than starvation.
WDFY3 can interact with the core autophagy promoting machinery, like p62, ATG5,
ATG12, and LC3 [173]. Interestingly, TGFβ has been shown to selectively activate
autophagy in human cancers, and in triple-negative breast cancers this can be an
oncogenic force [174, 175]. STAT3 is a well established oncogenic transcription factor
that is activated or elevated expression in many tumor types [176]. Hyperactive
signaling through Janus kinase receptor (JAK) or over-expression of total STAT3
promotes G1/S transition to drive cell cycle progression and cell proliferation [177].
Notably, in triple-negative breast cancers STAT3 can promote autophagic-addiction and
selective sensitivity to drugs targeting autophagy bafilomycin and chloroquine [178].
Given that WDFY3-AS2 regulates both WDFY3 and STAT3 through TGFβ pathway, this
may provide a novel mechanism for cooperation between pathways in breast cancers.
This chapter will discuss role of WDFY3-AS2 in further detail.

Results

BB049 and human ortholog WDFY3-AS2 are regulated by TGFβ in
mammary epithelia. Mouse lncRNA BB049, a 659 base transcript on mouse
chromosome 5, was another transcript which we predicted to have a human ortholog.
BLAST analysis showed that BB049 is not only conserved in human (78% identity, 26%
coverage), but across several species with >75% identity (Figure 25A). Importantly,
BB049 maps to annotated human lncRNA WDFY3-AS2, providing independent
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validation that our strategy for discovering human orthologs is effective (Figure 25B).
Given both BB049 and WDFY3-AS2 are already in NCBI ref seq database, we designed
primers for RT-qPCR based on these sequences. We confirmed that TGFβ treatment
significantly induces both mouse and human transcripts greater than 2-fold in NMuMG
and HMEC, respectively. (Fig 25C-D).

Figure 25. BB049 and human ortholog WDFY3-AS2 are regulated by TFGβ in
mammary epithelia. (A) Using BLAST analysis, BB049 is well conserved across
several species. (B) BB049 maps to human ortholog lncRNA at chromosome 4q21. (C)
NMuMG and (D) HMEC were treated with 5ng/ml TGFβ for 24 h and RT-qPCR was
performed to check expression of BB049 and WDFY3-AS2. Asterisks represents p<0.05.
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WDFY3-AS2 is elevated in human cancer and associates with lymph node
metastasis, high grade tumor, triple-negative subtype, and poor patient survival.
Since WDFY3-AS2 is elevated upon TGFβ-induced EMT in HMEC, we evaluated its
expression level in human breast cancer. We obtained fresh frozen patient RNA from 16
normal breast epithelia and 32 primary breast tumor samples from H. Lee Moffitt Cancer
Center Tissue Core. Semi-qPCR analysis showed that expression of WDFY3-AS2 is
elevated in breast tumors as compared to normal controls, suggesting that this
transcript may be functionally relevant in patient (Figure 26A). We next performed TMAISH that was blindly scored by a pathologist based on 2 criteria, percentage of positive
cells and staining intensity. The breast TMA is composed of cores of normal epithelia,
DCIS, IDC, and metastasis. We observed significant elevated expression of WDFY3AS2 in DCIS, IDC and metastatic lymph node as compared to normal (Figure 26B).
High levels of WDFY3-AS2 were associated with high grade tumor, positive lymph node
metastasis, and triple-negative subtype (Figure 26C). Furthermore, high expression of
WDFY3-AS2 correlated with overall poorer patient survival (Figure 26D). Collectively,
these data suggest that WDFY3-AS2 is involved in breast cancer initiation and
progression.

WDFY3-AS2 regulates TGFβ-induced EMT in HMEC. HMEC cells treated with
TGFβ will become more spindle-shaped and elongated, and protein expression levels of
E-cadherin will decrease, while Vimentin protein expression will increase. Since
WDFY3-AS2 is induced in response to TGFβ, we hypothesized that WDFY3-AS2 may
functionally contribute to TGFβ-induced EMT. To test this, we first designed 2 siRNAs
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Figure 26. WDFY3-AS2 is over-expressed in breast cancer and is associated with
poor patient survival and triple-negative breast cancer. (A) Semi-RT-qPRC analysis
of WDFY3-AS2 expression in 16 normal breast epithelia and 32 primary human breast
tumors. (B) TMA-ISH was performed on breast cancer TMA to assess expression of
WDFY3-AS2 at various stages of breast lesions. (C) Relation of expression of WDFYAS2 with clinical parameters. (D) Overall patient survival was analyzed and represented
as Kaplan-Meier Curve.
against WDFY3-AS2 (si-AS2-1 and si-AS2-2) and validated knockdown in MD-AMB-231
cell line which expresses high level of WDFY3-AS2. We next transfected HMEC cell
using control siRNA (si-CTL) and best scoring si-AS2-1 for 48 h, and then treated cells
with TGFβ to induce EMT for 24 h. Si-AS2-1 was able to almost completely eliminate
the induction of WDFY3-AS2 in response to TGFβ treatment (Figure 27A). Compared to
untreated control (UNT), TGFβ treated samples showed significant loss of E-cadherin
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and gain of Vimentin protein expression in si-CTL treated cells. However, both of these
responses were partially abolished in cells depleted WDFY3-AS2 by si-AS2-1 (Figure
27B). This result was also reaffirmed using immunofluorescence staining to visualize Ecadherin and Vimentin expression on the cell surface (Figure 27C).

Figure 27. Knockdown of WDFY3-AS2 inhibits TGFβ induced EMT. (A) HMEC was
left untreated (UNT) or transfected with control siRNA (si-CTL) or siRNA against
WDFY3-AS2 (si-AS2-1) for 48 h, and then treated with TGFβ for 24 h. Total RNA was
isolated and examined for WDFY3-AS2 expression by RT-qPCR. Similarly treated cells
were assessed for characteristic EMT markers, E-cadherin and Vimentin, by Western
blot (B) and immunofluorescence staining (C).

WDFY3-AS2 regulates migration, invasion, proliferation, and cell cycle.
TGFβ treatment increases cell migration and invasion in HMEC cell line similar to the
NMuMG cell line. To test WDFY3-AS2’s contributed to this, we pre-treated HMEC cells
for 24 hours with TGFβ (5 ng/ml) and then transfected si-CTL, si-AS-1, or si-AS2-2 for
48 hours while still in the presence of TGFβ. After 72 h of this treatment, we noticed a
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significant loss of WDFY3-AS2 expression using both siRNAs (Figure 28A). We then
assayed for cell migration and invasion using Boyden chambers. In both cases, TGFβinduced migration and invasion were significantly reduced upon depletion of WDFY3AS2 in HMEC compared to si-CTL control (Figure 28B and 28C).

Figure 28. Knockdown of WDFY3-AS2 inhibits TGFβ-induced migration and
invasion. (A) HMEC cells were pre-treated for 24 hours with TGFβ (5ng/ml) to induced
migration and invasion, and then transfected for 48 hours with si-CTL or siRNAs against
WDFY3-AS2. At 72 hours RNA was isolated and examined for WDFY3-AS2 expression.
Once knockdown was confirmed, cells were subjected Boyden 2-Chamber Assay
without matrigel (B) and with matrigel (C) to assess cell migration and invasion,
respectively.
We performed similar assays using highly metastatic MD-AMB-231 human cell
line. In these experiments, we knocked down WDFY3-AS2 for 48 hours, then placed
cells in top of Boyden chambers in serum free medium, and initiated cell motility using
10% serum containing media as chemo-attractant in bottom chamber. Again, after 16
hours we observed that cell migration and invasion were significantly reduced following
knockdown of WDFY3-AS2 (Figure 29A-B). MD-AMB-231 cell line was also assayed
for changes in proliferation after WDFY3-AS2 knockdown by EdU incorporation. Cells
were seeded in chamber slides at 70% confluence and transfected with si-CTL, si-AS2-
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1, and si-AS2-2 for 48 hours. The mean number of positive proliferating cells was
calculated by quantifying 4 non-biased fields. Cells treated siRNAs against WDFY3-AS2
showed significant reduction of percentage of cells with EdU incorporation (Figure 29C).
To further investigate contribution of WDFY3-AS2 to cell cycle progression in MD-AMB231, after 48 hours knockdown we fixed cells in ethanol and stained nuclear DNA with
propidium iodide (PI). In cells depleted WDY3-AS2, we observed a significant
accumulation of cells in G1-phase, and a decrease in S-phase and G2-phase
populations (Figure 29D). These data suggest that WDFY3-AS2 regulates cell
proliferation, DNA synthesis and G1-S transition.
Next we wanted to determine if over-expression of ectopic WDFY3-AS2 could
also have an effect on invasion, proliferation, and cell cycle. We cloned a 759nt cDNA
into pcDNA3.1 expression vector (pcDNA-AS2). Ectopic expression of pcDNA-AS2 in
low metastatic MCF7 cells caused an increase in invasion and EdU incorporation
(Figure 30A-B). We also performed PI staining and cell cycle analysis on MCF7 cells
over-expressing WDFY3-AS2 for 48 hours. Ectopic expression resulted in an increase
of both S-phase and G2-phase cells, and a decrease in G1-population (Figure 30C).

Knockdown of WDFY3-AS2 inhibits primary tumor growth and metastasis
in vivo. We next investigated whether WDFY3-AS2 knockdown resulted in reduced
motility and proliferation in vivo. To test this, we employed an orthotopic mouse
xenograft model by injecting 4 x 106 MD-AMB-231-Luciferase cells which had been
treated with si-CTL and si-AS2-1, into the lower mammary fat pad. Using the NSG mice,
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primary tumors were detected and established by the end of week 2. The size of the
primary tumor and the presence of lung metastasis were measured each week via

Figure 29. Knockdown of WDFY3-AS2 in MD-AMB-231 reduces migration,
invasion, proliferation, and G1 accumulation. (A and B) WDFY3-AS2 was knocked
down using 2 siRNAs in the highly metastatic cell MD-AMB-231 for 48 hours. Migration
was subsequently assessed by seeding cells in Boyden 2 Chamber without (A) and with
(B) matrigel. (C) Cell proliferation was assessed by incubation of cell with thymidine
nucleoside analogue 5-ethynyl-2´-deoxyuridine (EdU) for one hour. (D) Cell cycle
analysis was performed using propidium iodine (PI) staining of nuclei and followed flow
cytometry. Asterisks denotes p<0.05.

standard caliper measurement and bioluminescent imaging. The growth and size of the
primary tumor were significantly less in the mice injected with cells depleted WDFY3AS2 at week 5 and throughout endpoint at week 7 (Figure 31A-C). WDFY3-AS2
knockdown group also had significantly less tumor weight compared to control (Figure
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31D). At week 7 endpoint, both groups of mice were injected with luciferase substrate
and lungs were assessed for photon flux signal. There was a dramatic and significantly

Figure 30. Ectopic expression of WDFY3-AS2 increases invasion, proliferation,
and G2-S population. (A and B) pcDNA-AS2 was transfected into low metastatic
MCF7 cells for 48 hours. Invasion (A) and proliferation (B) were assayed using Boyden
chamber and EdU incorporation. (C) Cells were stained with PI to examine change in
cell cycle. Asterisks represents p<0.05.
more robust signal of luciferase in lungs of control mice compared to mice injected with
the cells depleted WDFY3-AS2 (Figure 31E). Lungs from each group were paraffin
embedded, sectioned, and H&E stained. The number of lung metastasis nodules for
each group was counted across 3 different sections per lung and averaged. There was
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a significant decrease in number of lung nodules present in WDFY3-AS2-knockdown
mice as compared to control mice (Figure 31F).

WDFY3-AS2 regulates protein coding gene WDFY3 and STAT3 via ‘cis’
‘trans’ mechanism. There are several examples of antisense lncRNAs regulating
closest neighboring protein coding gene in “cis” and regulating distant genes in “trans”
[56, 80, 149, 179]. In order to determine which genes are possible targets of WDFY3AS2, we performed Affymetrix Chip Gene Expression analysis on si-CTL or si-AS2-1
transfected MD-AMB-231 cells (Figure 32A). We observed 2 genes, WDFY3 and
STAT3 to be significantly down-regulated in response to WDFY3-AS2 knockdown. To
validate this finding, we designed real-time PCR primers for WDFY3 and STAT3 and
evaluated RNA expression for both after WDFY3-AS2 knockdown compared to control.
Consistent with the array data, we observed a significant decrease in both WDFY3 and
STAT3 mRNA levels after depletion of WDFY3-AS2 by semi-qPCR (Figure 32B).
Furthermore, we also observed a loss in total WDFY3, phospho-STAT3 and total
STAT3 at 72 hours knockdown of WDFY3-AS2 in MD-AMB-231 cells (Figure 32C).
Interestingly, if we first deplete cells of endogenous WDFY3-AS2 by siRNA
treatment, ectopic expression of pcDNA-WDFY3-AS2 construct was able to completely
rescue mRNA level of WDFY3 and partially rescue STAT3 (Figure 32D and 32E). In
MCF7 cells, ectopic expression of pcDNA-WDFY3-AS2 increased phosph-STAT3 and
total STAT3 protein, however this effect was not seen with WDFY3 protein level (Figure
32F).
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WDFY3-AS2 and WDFY3 are co-expressed and elevated WDFY3 is also a
predictor of poorer patient survival. Since WDY3-AS2 positively regulates WDFY3,
we next assessed the significance of WDFY3 protein expression in human breast
tumors and then correlated expression of WDFY3 with WDY3-AS2.

Figure 31. Knockdown of WDFY3-AS2 significantly inhibits tumor growth and
metastasis. (A and B) Stable expressing luciferase MD-AMB-231 cells were
transfected with si-CTL or si-AS2-1 for 48 hours. Cells were washed in PBS, trypsinized,
resuspended in PBS, and 4 x 106 cells were injected into lower mammary fat pad per
mouse. Primary tumor growth was tracked by bioluminescent imaging (A) and caliper
measurement (B).
(C) Quantification of primary tumor size using photon flux
measurement at week 5. (D) Tumors were removed from each mice and weighed.
Average mean and deviation are plotted. (E) At endpoint week 7, lungs metastasis were
imaged using bioluminescent. (F) Lungs from mice were paraffin embedded, sectioned,
H&E stained, and number of metastasis were counted and averaged.
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Immunohistochemical staining the same breast cancer TMAs was performed with
antibody against WDFY3. In a total of 135 specimens (normal, DCIS, and IDC), we
observed 43 cases (31.8 %) of low/low expression (WDFY3-AS2/WDFY3), 40 cases
(29.6 %) high/high expression, 22 cases (16.2 %) high/low expression, and 30 cases
(22.2 %) low/high expression. Plotting data in a 2 x 2 contingency table statistical

Figure 32. WDFY3-AS2 regulates protein coding gene WDFY3 and STAT3. (A) MDAMB-231 cells were treated with si-CTL or si-AS2-1 for 48 hours and Affymetrix Gene
Expression Analysis was performed. WDFY3 and STAT3 mRNA were shown to be
significantly down-regulated in response to WFY3-AS2 knockdown. (B) Semi qRT-PCR
analysis of WDFY3 and STAT3 expression. (C) Western blot protein analysis of WDFY3,
phosho-STAT3, and total STAT3 protein in MD-AMB-231 cells treated with si-AS2-1, siAS2-2 and si-CTL. (D and E) WDFY3 and STAT3 mRNAs were rescued with
introduction of pcDNA-WDFY3-AS2 after knockdown of endogenous WDFY3-AS2. (F)
Over-expression of pcDNA-WDFY3-AS2 construct induces phospho-STAT3 and total
STAT3 protein levels.
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analysis demonstrated a significantly positive correlation between expression WDFY3AS2 (RNA) and WDFY3 (protein) in patients with breast cancer (Figure 33A-B).
Furthermore, we also observed co-expression of WDFY3-AS2 and WDFY3
(mRNA) in 15 established breast cancer cell lines as measured by RT-qPCR and
plotted by linear regression and R-squared analysis (data not shown). Collectively,
these data suggest that WDFY3-AS2 positively regulates WDFY3 expression in vivo.
Since we have shown that WDFY3-AS2 is strongly associated with triple-negative
subtype and high grade tumor (Figure 26), we used Kaplan Meier Plotter Database for
independent validation and found that elevated WDFY3 is also a predictor of poorer
overall survival. In patients stratified for ER-negative, basal subtype, or high grade
breast cancers, elevated WDFY3 mRNA is a significant predictor of poorer patient
survival in all 3 cases (Figure 33C-E). Interestingly, elevated WDFY3 mRNA is of no, or
reverse, prognostic value in patients with ER-positive, luminal A subtype, or low grade
tumor (data not shown).
Since WDFY3 and STAT3 are the targets of WDFY3-AS2, we next examined
their expression in orthotopic mouse breast tumors derived from WDFY3-AS2
knockdown and si-CTL transfected MDA-MB-231 cells. Immunoblot analysis revealed
decreased expression of both WDFY3 and STAT3 in WDFY3-AS2 depleted tumors
(Figure 34A).

Furthermore, immunohistochemical staining and in situ hybridization of

paraffin embedded sections of xenograft tumor and lungs showed significantly reduction
of STAT3 and WDFY3 expression in WDFY3-AS2 knockdown breast tumor and lung
metastases. In addition, Ki-67 proliferation marker was also significantly reduced in siAS2-1 treated group (Figure 34B).
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WDFY3-AS2 binds to hnRNP-R to regulate WDFY3 and STAT3. In attempt to
identify a protein binding partner for WDFY3-AS2, RNA immunoprecipitation (RIP)
assay was performed. “Sense” and “Antisense” orientations of WDFY3-AS2 RNA were
in vitro transcribed in the presence of biotin-UTP and mixed with 1 mg of MD-AMB-231
nuclear extract. Ribonucleoprotein (RNP) complexes were immunoprecipitated using
agarose-streptavidin.

The bound protein was run on an SDS page gel and silver

stained for analysis (Figure 35A). We observed a unique protein band in the “sense”
lane just below the 72-kDa protein marker. This band was extracted and submitted for
protein identification via mass spectrometry. Analysis revealed a significant enrichment
of hnRNP-R protein as compared to “antisense” gel band extracted at same molecular
weight. To confirm this interaction, we transfected hnRNP-R-FLAG construct into
HEK293T cells for 72 hours and performed RIP assay using biotinylated “sense” and
“antisense” RNA probes. After immunoprecipitation using streptavidin-agarose,
immunoblotting for FLAG showed a significant enrichment in sense binding to hnRNP-R
versus antisense probe (Figure 35B). We performed similar experiments using 1 mg
nuclear extract isolated from MDA-MB-231 cell line and immunoblotting against
endogenous hnRNP-R (data not shown).
Next we performed the reverse experiment to assess binding of endogenous
WDFY3-AS2 to hnRNP-R. We transfected either vector or hnRNPR-FLAG into MDAMB-231 cells for 72 hours followed by immunoprecipitation using FLAG antibody. Total
RNA was isolated from the immunoprecipitates. Semi-qPCR and real-time PCR was
performed to examine endogenous WDFY3-AS2 binding to hnRNP-R. We observed
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Figure 33. WDFY3-AS2 and WDFY3 are co-expressed in patient and elevated
WDFY3 predicts poorer patient overall survival. (A) WDFY3-AS2 and WDFY3 were
stained using LNA-probe and antibody, respectively. They are significantly coexpressed. (B) Representative tissue cores demonstrating increased co-expression of
both WDFY3-AS2 and WDFY3. (C - D) In stratifying patients, WDFY3, like WDFY3-AS2,
is also a predictor of poorer overall survival in ER-negative (C) basal subtype (D) and
grade III tumors (E).

about an 8-fold increase in bound WDFY3-AS2 transfected with hnRNP-R-FLAG as
compared to that transfected with vector (Figure 35C). Endogenous hnRNP-R in MDAMB-231 and MCF7 cell lines was also evaluated for bound endogenous WDY3-AS2 by
comparing immunoprecipitations of anti-hnRNPR and anti-GFP. In both cell lines we
found greater than 2-fold increase in bound WDFY3-AS2 compared to GFP control
(Figure 35D).
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Figure 34. Reduced expression of WDFY3 and STAT3 in WDFY3-AS2 knockdown
orthotopic mouse breast tumor and lung metastatic lesions. (A) Depletion of
WDFY3-AS2 in MDA-MB-231 xenograft of primary tumor results in decreased
expression of both WDFY3 and STAT3 protein. (B) Primary tumor and lungs were
removed, paraffin embedded, and stained with H&E, LNA-WDFY3-AS2 RNA probe, and
antibodies against WDFY3 and STAT3, as well as Ki-67.
Previously we have shown that knockdown of endogenous WDFY3-AS2 followed
by introduction of ectopic WDFY3-AS2 can rescue both WDFY3 and STAT3 RNA levels.
To assess whether hnRNP-R functionally contributes to this process, we performed the
same rescue experiments and included cells deficient in hnRNP-R. We noticed that in
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cells depletion of hnRNP-R, we were unable to restore WDFY3 and STAT3 mRNA
(Figure 35E). This denoted that WDFY3-AS2 promotes WDFY3 and STAT3 expression
in an hnRNP-R dependent manner.

Discussion

We identified a long non-coding mouse transcript BB179049 to be significantly
up-regulated in response to TGFβ, which was mapped to syntenic loci and shared
sequence with human ortholog WDFY3-AS2. We have shown that WDFY3-AS2 is also
induced by TFGβ in human HMEC cells, and this regulation in mammary epithelia is
conserved from mouse to human. We observed WDFY3-AS2 to be elevated in several
breast cancer cell lines and primary breast tumors compared to normal controls.
Furthermore, WDFY3-AS2 expression directly increases with progression of disease,
and is most significantly overexpressed in metastatic lesions. WDFY3-AS2 also has
clinical and pathological significance in that elevated expression of WDFY3-AS2 is a
predictor of poorer overall survival, as well as associates with last stage and high grade
tumors as well as triple-negative breast cancer subtype. Depletion of WDFY3-AS2
slowed the onset of TGFβ mediated EMT program and also inhibited migration, invasion,
and proliferation. These results were recapitulated in a mouse orthotopic xenograft
model in that mice deficient in WDFY3-AS2 showed decreased primary tumor growth
and lung metastasis.
WDFY3-AS2 is a natural antisense transcript (NAT) located at the 5-prime region
but not overlapping with protein coding gene WDFY3. Several examples of NATs are
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emerging in literature and it is becoming more apparent that a large subset of protein
coding genes may be regulated by these lncRNAs [180-183]. Here we have shown that
knockdown of WDFY3-AS2 transcript results in loss of WDFY3 transcript and protein.

Figure 35. WDFY3-AS2 binds to hnRNP-R. (A) RNA-Immunoprecipitation (RIP) was
performed using biotinylated “sense” and “antisense” probes and 1mg MDA-MB-231
nuclear extract. Total bound RNA-protein complexes was run on SDS-page gel and
silver stained. (B) HEK293T cells were transfected with ectopic hnRNP-R-FLAG. After
48 h of incubation, RIP was performed. Subsequent Western blotting was done using
anti-FLAG antibody. (C and D) MDA-MB-231 cells were transfected with hnRNP-RFLAG. IP was performed after 72 h, total RNA was isolated from IPs and checked for
endogenous WDFY3-AS2 expression by semi-qPCR (C) and real-time PCR (D). (E)
Endogenous hnRNP-R was knocked down using siRNA and then co-transfected with
pcDNA-AS2. WDFY3 and STAT3 mRNAs were assessed by RT-qPCR.
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The

WDFY3

gene

encodes

for

a

protein

that

enhances

selective

macroautophagy through interaction with p62 and the autophagy effector complex
consisting of Atg5, Atg12, Atg16, and LC3 [173]. Another report has demonstrated that
autophagy promotes cell invasion and EMT in hepatocellular carcinoma using TGFβ
pathway as a key regulatory element [184]. Studies have also shown that potent
inhibitors of autophagy can have therapeutic benefit in specifically in triple-negative
breast cancer subtype including those driven by STAT3 [175, 178, 185]. For this reason,
we found it interesting that elevated WDFY3 associates with poorer patient overall
survival in these ER-negative and basal subtype, but not ER-positive or luminal subtype
of breast cancer.
We have also identified STAT3 as a downstream target of WDFY3-AS2. STAT3
is a well-established oncogene across several human malignancies [186-188]. The
JAK/STAT signaling pathway has also been shown to be critical for EMT, invasion, and
metastasis [189, 190]. One report has demonstrated that there is therapeutic benefit
using metformin to target STAT3 specifically in triple-negative breast cancer [191]. Our
data suggest that WDFY3-AS2 is a novel route for TGFβ mediated activation of STAT3
to enhance both proliferation and EMT phenotypes in breast cancer.
We have identified hnRNP-R to be a protein binding partner of WDFY3-AS2, and
this interaction functions to regulate WDFY3 expression. It has recently been reported
that hnRNP-R can facilitate transcription through its interaction with scaffolding
components Mediator, TBP, and TFIIH, which can then recruit RNA polymerase II [192].
Since WDFY3-AS2 lies in the antisense orientation and upstream to the transcriptional
start site of WDFY3, this may provide a novel mechanism by which lncRNA can recruit
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RNA polymerase II to the promoter to activate target gene transcription. However,
further experimentation is required to solidify this claim.
Taken together, WDFY3-AS2 is a novel target for therapy in triple-negative
breast cancer. Since we have shown that WDFY3-AS2 is critical for expression of both
WDFY3 and STAT3, inhibition of WDFY3-AS2 could suppress associated phenotypes
facilitated through the function of these two genes. WDFY3-AS2 can also serve as a
novel biomarker for diagnostic and prognostic utility in the clinic. Future studies in this
area of research are warranted.

Methods

Invasion and migration assays. Briefly, MD-AMB-231 cell were transfected
with si-CTL, si-AS2-1, and si-AS2-2 for 48 hours. Cells were washed in PBS, trypsinized,
and seeded in upper chambers without (migration) and with matrigel (invasion). After 16
hours top chambers were cleared with cotton, and bottom chamber was fixed in crystal
violet plus 10% methanol. Average mean and standard deviations were calculated from
4 non-biased fields.

Cell Lines, treatment, and tumor specimens. Cells were obtained from ATCC
and grown according to recommended conditions. MD-AMB-231 and MCF7 cell lines
were maintained in RPMI plus 10% fetal bovine serum. Cell transfections were
performed using Lipofectamine 2000. Frozen RNAs were procured anonymously from

99

patients at H. Lee Moffitt Cancer Center, and approved by the IRB. Tissues were snapfrozen to avoid degradation and isolated with Trizol.

Locked nucleic acid in situ hybridization of formalin-fixed, paraffinembedded tissue microarray (LNA-TMA-ISH). WDFY3-AS2 LNA probe was prepared
by

end

labeling

with

digoxigenin-ddUTP

terminal

transferase.

Following

deparaffinization and antigen retrieval, TMAs were hybridized with 10 nmol/L LNA
WDFY3-AS2 probe in a hybridization buffer for 12 hours. After washing 4× SSC/50%
formamide, 2× SSC, and 0.1× SSC, sections were blocked for 1 hour and incubated
with anti-DIG-AP Fab fragments. Following washing in 1× maleic acid and 0.3% Tween
20 buffer, reactions were processed [100 mmol/L Tris-HCl (pH 9.5) and 100 mmol/L
NaCl] in the presence of nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate
and then visualized.

Mouse orthotopic breast cancer model. MD-AMB-231-Luciferase cell line was
transfected with si-CTL or si-AS2-1 for 48 hours. Cells were washed, trypsinzed, and
resuspended in PBS at a concentration of 4 x 106 cells per 100ul. Six-week old NSG
mice received 100ul injection into lower fat pad. Tumor volume and luminescence signal
were documented and imaged using Xenogen IVIS Imaging System 200 .

Affymetrix Gene Expression Array. As described in Chapter 3. Briefly, MDAMB-231 cells were transfected with si-CTL or si-AS2-1, total RNA was isolated and
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hybridized to the chip. Analysis was performed by H. Lee Moffitt Cancer Center
Molecular Genomics Core.

Immunoblotting Immunofluorescence, and antibodies. Western blotting was
performed using standard procedures. Antibodies against WDFY3 and total STAT3 was
purchased from Santa Cruz Biotechnologies (Santa Cruz, CA, USA), and phoshoSTAT3 was from Cell Signaling Technologies (Danvers, MA). For immunofluorescence
staining, HMEC cells were seeded onto glass cover slips and then transfected with
siRNAs for 48 hours. Media was then supplemented with TGFβ for times indicated in
figure legend. Cover slips were then washed in PBS and then fixed in 10% cold
methanol. Cover slips were then permeablized using 1% NP-40 and blocked in 10%
normal goat serum. Primary antibody incubation was performed overnight at 4 degrees
and secondary incubation was at room temperature for 1 hour. Cells were then washed
in TBS, counterstained with DAPI, and fixed with mounting media for visualization.

Plasmids and siRNAs. A 758nt insert of WDFY3-AS2 was amplified and TAcloned into pGEM-T-easy vector from Promega (Madison, WI, USA) using T47D cDNA
library as template. Plasmid containing insert was sequenced, insert was then isolated
by EcoRI restriction digest, and cloned into pcDNA3.1 (pcDNA-AS2). SiRNAs were
designed using IDT siRNA Design Software. Two siRNAs against human WDFY3-AS2
(si-AS2-1 and si-AS2-2) were determined empirically and used for experimentation.
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RNA immunoprecipitation (RIP) assay. WDFY3-AS2 sense and antisense
DNA templates were generated using standard PCR and incorporating a T7 RNA
polymerase II recognition site through the forward primer, respectively. PCR fragments
were purified and 1ug template was used for in vitro transcription reaction using
MAXIscript In Vitro Transcription Kit (Life Technologies) in the presence of biotin labeled
UTP Roche (Branchburg, NJ, USA). Protocol used was previously described. [49]
Briefly, 3ug in vitro transcribed RNA was incubated with 1mg nuclear extract,
immunoprecipitated with 60ul streptavidin beads (Life Technologies), and run on a SDSpage gel. Gel was silver stained, and unique bands in sense lane were submitted for
protein

identification

via
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mass

spectrometry.

CHAPTER 5
LncRNA TIL involved in breast cancer EMT, metastasis, and cancer cell
stemness through regulation of NF90/C-MYC

Introduction

Another mouse lncRNA AK060 was also found to be significantly up-regulated by
TGFβ in the microarray analysis and predicted to have a human ortholog. We were in
fact able to detect a conserved lncRNA also regulated by TGFβ in human HEMC cells
and was also elevated in human breast cancer. We have decided to refer to the human
lncRNA as TIL, because this is TGFβ Induced LncRNA. TIL was of particular interest
given its proximity to the C-MYC gene (e.g., residing ~10MB upstream of C-MYC) in
8q23-24 region. Recently, several reports have suggested that locally residing lncRNAs
can regulate C-MYC expression by various mechanisms [61, 86, 87]. Therefore this led
to the hypothesis that TIL may also regulate C-MYC expression.
Knockdown and over-expression studies demonstrated that TIL regulated CMYC protein expression, however, had no effect on C-MYC mRNA levels. These results
suggest TIL regulation of C-MYC at post-transcriptional level. We identified NF90 as a
binding partner for TIL. NF90 is a dsRBP capable of regulating target gene expression
through interaction with AU-rich elements (AREs) within the 3-prime UTR [193]. We
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next found that C-MYC messenger contains 4 AREs and also physically associates with
NF90, and this interaction likely stabilizes the mRNA. Furthermore, it has been reported
that AKT phosphorylation of NF90 at Ser647 is critical for NF90 shuttling from nuclear to
cytosol [194]. We have shown that TIL enhances phospho-NF90 level and promotes
NF90 export from the nucleus. Taken together, we hypothesize that TIL enhances
nuclear export of NF90 which increases C-MYC mRNA stability in cytosol and C-MYC
protein product. This chapter aims to discuss these mechanisms in further detail.

Results

TGFβ-regulated AK060 and human ortholog TIL. AK060 is a mouse lncRNA
predicted to have a human ortholog. In “BLAST-ing” mouse AK060 to the human
genome, we observed significant sequence conservation at intergenic region on
chromosome 8. AK060 is conserved across several species to varying degrees, and in
human exhibits 88% identity across 44% coverage (Figure 36A).
This result was interesting to us given the close proximity to the C-MYC gene
locus (~10MB; Figure 36B). There have been previous reports of lncRNAs residing
within this genomic region that regulate C-MYC [61, 86, 195]. Next we validated
regulation by TGFβ of AK060 and human ortholog in NMuMG and HMEC cell lines,
respectively (Figure 36C and 36D). In human, this conserved transcript is induced
greater than 3-fold in response to 24 hours TGFβ treatment versus vehicle control. We
thus named the human transcript TIL (TGFβ Induced LncRNA).
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Figure 36. AK060/TIL is a conserved TGFβ-upregulated lncRNA. (A) “BLAST”
analysis of mouse AK060 transcript showed significant sequence identity and coverage
at syntenic loci 8q23 in human. (B) Diagram shows that TIL is ~10 MB away from CMYC. (C) NMuMG and (D) HMEC were treated with TGFβ (5ng/ml) for 24 hours and
expression of AK060 and TIL were measured by RT-qPCR.
TIL is elevated in human breast cancer and associates with late stage
tumor and triple-negative breast cancer. We next evaluated TIL expression in a
panel of human breast cancer cell lines. In comparison to HMEC normal cell, several
cancer lines show significant over-expression of TIL, notably HS578T, MDA-MB-231,
SKBR3, and CAMA1 (Figure 37A). Furthermore, we obtained 16 normal and 32 primary
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breast tumor RNAs from H. Lee Moffitt Tissue Core. In the normal breast, semi-qPCR
showed almost no expression of TIL. However, TIL is frequently overexpressed in tumor
RNA samples (Figure 37B). Furthermore, we also obtained 8 pairs of adjacent normal
and breast tumor RNAs. In 6 of the 8 pairs we observed overexpression of TIL (Figure
37C).

Figure 37. TIL is elevated in breast cancer cell lines and primary tumors. (A) SemiqPCR for TIL expression was performed in a panel of e breast cancer cell lines. (B and
C) Indicated normal and breast tumors were subjected into semi-qPCR analysis for
expression of TIL.
Next, we performed in situ hybridization analysis on breast TMAs which contain
cores of normal epithelia, DCIS, IDC, and lymph node metastasis. A pattern emerged in
that TIL was shown to have progressively higher expression as disease became more
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advanced. For example, expression in DCIS was higher than normal, and expression in
IDC was higher than DCIS. The most significant overexpression was observed in the
metastasis (Figure 38A). Representative images were taken for cores in each group
(Figure 38B). Based on the data available, we assessed if there was any significant
association between elevated TIL and patient clinical and pathological characteristics.
Our analysis revealed that high expression of TIL correlates with late stage tumor,
positive lymph node metastasis, and triple-negative breast cancer (Figure 38C). There
was however no significant correlation with overall survival as shown by Kaplan-Meier
Plot (Figure 38D). This result may be due to a non-stratified population and the limited
number of breast cancer examined. For example, if we were to separate the population
into late-stage versus early-stage, or triple-negative versus ER-positive populations, we
may see significant survival data. In this study, however, there are very few patients
with late-stage and triple-negative breast cancer to make this conclusion (data not
shown). The prognostic value of TIL warrants further investigation.

TIL regulates migration, invasion, and has elevated expression in BCSCs.
Expression of TIL is high in the triple-negative and highly invasive MDA-MB-231 breast
cancer cell line. Therefore, we used this cell line to confirm knockdown of TIL
expression using 2 siRNAs (si-TIL-1 and si-TIL-2) compared to si-CTL (Figure 39A).
Once knockdown was confirmed, we assayed MDA-MB-231 for phenotypic changes in
migration and invasion. After 48 hours of TIL depletion, cells for each group were
seeded in upper chambers and assayed for migration and invasion. After 16 h, top
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Figure 38. TIL is progressively up-regulated with advanced disease and
associates with late stage tumor, positive lymph node, and triple-negative breast
cancer. (A) TMA-ISH was performed using LNA-probe and scored. (B) Representative
images of patients in each group are shown. (C) Correlation of clinical and pathological
data with TIL expression. (D) Kaplan-Meier curve representing overall survival.
chambers were cleared and number of migratory cells were quantified by 4 non-biased
fields. Loss of TIL resulted in significant reduction of both migration and invasion in
comparison to control (Figure 39B and 39C).
Next, a cDNA clone of TIL was generated using SKBR3 RNA as a template.
Primers were designed based on the large human exon conserved in human from
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mouse AK060. We called this region “Exon 3” and hypothesized this to contain
functional domain. As predicted we amplified a 657nt insert in which we cloned into the
pcDNA3.1+ expression vector. Next, we over-expressed TIL in MCF7 cells (Figure 39D).
Ectopic introduction was able to induce invasion capacity >3-fold compared to vector
control (Figure 39E).
To address if TIL is involved in regulation of breast cancer stem cell (BCSC)
property, we treated the HMEC cells with TGFβ (5 ng/ml) for 9 days. HMEC cells
underwent EMT in about 24 hours, and beyond this continually moved towards a stemlike status. Using this method, it is possible to generate a significant population of
CD44+/CD24- cells in culture, indicative of BCSC population. Next, the cells were
sorted by flow for CD44-/CD24+ and CD44+/CD24- populations and RNA was isolated.
RT-qPCR analysis showed that there was ~13-fold higher expression of TIL in the
BCSC population compared to non-BCSCs (Figure 39F).

TIL post-transcriptionally upregulates C-MYC. TIL locates at chromosome
8q23, about 10MB away from C-MYC gene. Due to close proximity, and ability of
lncRNAs to target neighboring gene expression in “cis”, we directly addressed whether
TIL regulates C-MYC. We first silenced TIL expression in MDA-MB-231 cell using siTIL-1 (Figure 40A). As shown in Figure 39A, this siRNA gives ~80% knockdown. Next,
we checked whether loss of TIL expression resulted in changes in C-MYC mRNA or
protein levels. Interestingly, we observed no change in C-MYC mRNA after TIL
knockdown, however we did detect significant drop in C-MYC protein expression
(Figure 40B and 40C). Furthermore, we introduced TIL into MCF7 cells and found that
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ectopic expression of TIL also had no effect on C-MYC mRNA, but dramatically induced
total C-MYC protein levels (Figure 40D-F).

Figure 39. TIL regulates migration, invasion, and has higher expression in BCSCs.
(A) MDA-MB-231 cells were transfected with si-CTL, si-TIL-1, and si-TIL-2 for 48 hours
and semi-qPCR was performed. (B and C) After 48 hours transfection, cells were
seeded in upper chamber for 16 h and assayed for migration (B) and invasion(C). (D)
pcDNA-TIL was transfected into MCF7 and measured by semi-qPCR. (E) After 48
hours transfection, MCF7 cells were seeded in upper chamber and assayed for invasion.
(F) HMEC cells were treated with TGFβ for 9 days and sorted by flow for CD44-/CD24+
and CD44+/CD24- populations. RNA was isolated and examined for TIL expression by
RT-qPCR. Asterisks represent p<0.05.
It has also been well documented that in normal breast and early onset of breast
cancer, TGFβ treatment will result in down-regulation of C-MYC mRNA and protein
expression [196]. In this case such as in HMEC, TGFβ pathway will act as a tumor
suppressor. However, in breast cancers where the “switch” has occurred, TGFβ
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treatment will induce C-MYC mRNA and eventual protein expression to trigger
oncogenic phenotypes. This is the case with MDA-MB-231 line, in which 24 h TGFβ
treatment (5ng/ml) induced C-MYC mRNA ~3-fold (Figure 40G). MDA-MB-231 cells
were transfected with si-CTL and si-TIL for 48 hours and left untreated or treated with
TGFβ for 24 hours. In the absence of TIL, TGFβ-induced C-MYC mRNA levels remain
unaffected after 24 hours (Figure 40G). Interestingly, C-MYC protein expression is
dramatically inhibited as shown by time course of TGFβ treatment (Figure 40H). This
result suggests that TIL post-transcriptionally regulates C-MYC expression.

TIL binds to NF90. To elucidate the mechanism by which TIL posttranscriptionally regulates C-MYC, we aimed to identify a protein binding partner. To do
this we used the non-biased RIP assay described in Chapter 4.

Briefly, in vitro

transcribed biotinylated “Sense” and “Antisense” TIL RNAs were incubated with 1mg
MDA-MB-231 protein extract. RNA-protein complexes were immunoprecipitated using.
Streptavidin-agarose, washed, boiled, and run on SDS-page gel. We observed a
very strong unique band at ~90 kDa in the “Sense” lane that was not visible in the
“Antisense” lane (Figure 41A). This band was excised and subjected to mass
spectrometry protein identification. The data suggested a strong enrichment for the
NF90 protein in “Sense” versus “Antisense” samples. To further investigate the
interaction of TIL with NF90, we performed similar RIP experiment as described above
with minimal modification. After running SDS-page gel, total bound proteins were
transferred to nitrocellulose membrane. Western blotting analysis was carried out with
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an antibody against NF90. We observed significant expression of NF90 in “sense” lane
and virtually no expression in the “antisense” lane (Figure 41B).

Figure 40. TIL regulates C-MYC at protein but not mRNA level. (A) MDA-MB-231
cells were transfected with si-CTL and si-TIL-1 and subsequently subjected into realtime PCR analysis of TIL expression. (B and C) After 48 hours of knockdown of TIL, CMYC mRNA and protein expression was measured by RT-qPCR (B) and Western blot
analysis (C). (D - F) MCF7 cells were transfected with pcDNA-TIL and vector control.
Following 48 hours of incubation, RT-qPCR was performed to examine the expression
of transfected plasmids (D) and C–MYC mRNA (E). C-MYC protein levels were
assessed by western blotting (F). (G) MDA-MB-231 cells were transfected with si-CTL
and si-TIL-1 for 48 h. Samples were left untreated or treated with TGFβ (5 ng/ml) for 24
hours. Total RNA was isolated and expression of TIL and C-MYC mRNA was assessed
by RT-qPCR. (H) Cells were similarly transfected as described in panel G. Following
treatment with TGFβ for indicated time, immunoblot analysis was performed with anti-CMYC antibody. GAPDH was used as a loading control.
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Next, we performed the reverse experiment to see if NF90 bound endogenous
TIL in vivo. To do this, we lysed MDA-MB-231 cells, and then incubated with anti-GFP
or anti-NF90 antibodies. Immunoprecipitation was performed using protein A/G beads
and total bound protein-RNA complexes were resuspended in Trizol buffer. Total RNA
was then isolated and semi-qPCR was performed. We observed a significant
enrichment of endogenous TIL in the anti-NF90 samples as compared to anti-GFP
(Figure 41C). These results suggest that endogenous NF90 binds to endogenous TIL in
vivo.

C-MYC binds to NF90. Since TIL induces C-MYC protein level and binds to
NF90, we next investigated if NF90 mediates TIL effect on C-MYC. NF90 is known to
bind AU-rich elements (AREs) within the 3’UTR of mRNAs to influence target gene
expression. NF90 can be bi-faced and multifunctional in that it can promote mRNA
stability and degradation, as well as facilitate nuclear export of transcripts to the cytosol
[197, 198]. We therefore analyzed the 3’UTR of C-MYC for presence of AREs using
“AREsite” software [199] and found four distinct AUUUA motifs within 3’UTR of C-MYC
(Figure 42A).
Furthermore, we cloned C-MYC 3’UTR (e.g., 474nt) into pcDNA3 vector for in
vitro transcription. Next, we generated biotinylated “sense” and “antisense” RNA probes
and performed similar RIP experiment with MDA-MB-231 extract as described above to
assess whether the 3’UTR of C-MYC binds to NF90. Indeed, after isolating RNA-protein
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Figure 41. TIL binds to NF90. (A) RIP was performed by incubation of 3ug biotinylated
“sense” and “antisense” RNAs of TIL with 1mg MDA-MB-231 extract in the presence of,
Streptavidin-agarose. Following wash, total bound protein was run on SDS-page gel
and silver stained. Unique bands were subjected to protein identification by mass
spectrometry. (B) Similar RIP was performed and total bound protein was transferred to
nitrocellulose for Western blot analysis with NF90 antibody. (C) Immunoprecipitates
were prepared with antibodies against GFP and NF90 and then were used to isolate
RNA. Endogenous TIL expression was evaluated with semi-qPCR.
complexes by Streptavidin-agarose, Western blot analysis showed a strong enrichment
for NF90 in “sense” but not “antisense” (Figure 42B). Next, we performed IP on
endogenous NF90 and confirmed interaction with C-MYC mRNA transcript in vivo by
semi-qPCR (Figure 42C). Taken together, these data suggest that the C-MYC 3’UTR
contains AREs which interact with NF90.
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TGFβ induces TIL-dependent shuttling NF90/C-MYC to cytosol. We next
investigated the significance of TGFβ stimulation in relation to the TIL/NF90/C-MYC
interaction. Since NF90 can stabilize transcripts in the cytosol to enhance protein
expression and since NF90 binds to C-MYC mRNA, We hypothesized that TGFβ and
TIL may facilitate this process. First, we treated the MDA-MB-231 with TGFβ to examine
for change of NF90 localization. Indeed, TGFβ significantly induced shuttling of NF90
from nuclear to cytosol following the treatment for 24 hours (Figure 43A). However, if
cells are first depleted TIL using siRNA, NF90 shuttling in response to 24 hours TGFβ
treatment is almost completely abolished (Figure 43B). In the low-TIL expressing BT474
cell line, ectopic expression of TIL can enforce NF90 shuttling from nuclear to cytosol,
however has no effect on total NF90 protein levels (Figure 43C). This result suggests
that TIL/NF90 interaction is important for NF90 shuttling from nuclear to cytosol.
Since C-MYC mRNA also binds to NF90, we tested whether TIL can also drive
C-MYC mRNA to cytosol. We ectopically expressed TIL in BT474 and observed that TIL
promoted C-MYC mRNA from nuclear to cytosol. Presumably this shuttling is through
C-MYC mRNA being bound to NF90 (Figure 43D). We have shown that ectopic TIL
results in increased C-MYC protein, likely the result of increased C-MYC mRNA. To
further demonstrate that ectopic TIL increase of C-MYC protein is through C-MYC
3’UTR interaction with NF90, we cloned the 3’UTR of C-MYC into luciferase reporter
construct (pMIR-Luciferase-3’-UTR-C-MYC). Cells were first transfected with reporter
alone or 3’UTR containing reporter. After 24 hours, cells were co-transfected with
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Figure 42. NF90 binds to C-MYC 3’UTR. (A) AREsite software identified four AUUUA
motifs within the 3’UTR of C-MYC. (B) Three microgram biotinylated “sense” and
“antisense” C-MYC 3’UTR RNA probes were incubated with 1mg MDA-MB-231 extract.
Western blotting was performed for NF90 interaction with 3’UTR of C-MYC. (C) AntiGFP and anti-NF90 were incubated with MDA-MB-231 extract and then
immunoprecipitated in the presence of protein A/G. Total RNA was isolated and semiqPCR was performed for C-MYC mRNA.
pcDNA or pcDNA-TIL. In cells co-transfected with 3’UTR containing reporter and TIL
(V2+TIL), bioluminescence activity was significantly increased compared to controls.
(Figure 43E). Taken together, these results suggest that TIL forces C-MYC mRNA to
the cytosol, and this shuttling is dependent on the 3’UTR of C-MYC.

TIL enhances AKT phosphorylation of NF90 at Ser647. A previous report has
demonstrated that phosphorylation of NF90 at Ser647 by AKT is essential for NF90
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shuttling out of the nucleus to cytosol for binding and stabilization of IL-2 [194, 198]. We
therefore hypothesized that TIL may be involved in this phosphorylation event. To test
this, we transfected MCF7 with vector and TIL, and then NF90 was immunoprecipitated.
Since no antibody exists for NF90-p-Ser647, we probed the Western blot using

Figure 43. TGFβ enhances TIL-dependent NF90 and C-MYC mRNA shuttling to
cytosol. (A) MDA-MB-231 cells were treated with TGFβ (5 ng/ml) and cells were
fractioned to check for localization of NF90. (B) Cells were transfected with si-CTL or siTIL for 48 hours and then treated with TGFβ for 24 hours. Cells were fractioned for
Western blot analysis with NF90 antibody. (C and D) BT474 cells were transfected with
ectopic TIL and fractioned for Western blot for NF90 (C) and RT-qPCR for C-MYC
mRNA (D). (E) HEK293 cells were transfected with V1 (pMIR-Luciferase) or V2 (pMIRLuciferase-3’UTR-C-MYC) for 24 hours. Cells were co-transfected with pcDNA or
pcDNA-TIL for 48 hours. At total 72 hours time point, cells were lysed and luciferase
activity was measured.
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phospho-AKT-substrate antibody, which recognizes the RXRXXS/T motif of typical AKT
phosphorylation. We observed a significant increase in signal in cells transfected with
TIL at band consistent with size NF90. However, after stripping and reprobing the blot
we observed no change in total NF90 levels (Figure 44A). It is important to note that
Ser647 is the only residue of NF90 being phosphorylated by AKT. Therefore any signal
observed using phospho-AKT-substrate antibody is indicative of p-Ser647. The same
result was observed by co-transfecting NF90-GFP with TIL (Figure 44B).
We further determine if loss of TIL results in a drop in p-Ser647 signal. Previously
it has been shown that TGFβ-induced EMT in mammary epithelia is through
downstream signaling of the AKT pathway. This report demonstrated that TGFβ
treatment coincided with activation of p-SMAD3/1 and p-AKT-473 [200]. Therefore, we
knocked down TIL for 48 hours in MDA-MB-231, and then treated cells for 30 minutes
with TGFβ to check for changes in p-Ser-647 of NF90. We observed a substantial
increase of p-Ser647 in si-CTL transfected cells treated TGFβ compared to untreated,
as predicted. However, if TIL was depleted prior to TGFβ treatment, NF90 p-Ser647
levels were completely lost to levels even below untreated cells (Figure 44C). These
results suggest that TIL is involved in enhancing the phosphorylation of NF90 at Ser647
by AKT.

Discussion

We propose a model by which TIL regulates C-MYC expression through the
RNA-binding protein NF90 (Figure 45). TIL and C-MYC locate ~10MB apart in the 8q23-
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24 locus, a region of the genome that has been implicated in several cancers. Elevated
expression of C-MYC has also been reported to be a driver in several malignancies
including breast cancer. We have demonstrated that TGFβ induces TIL and C-MYC
expression at RNA level. We have referred to this arm of TIL-pathway as the
“transcriptional” pathway, and likely TIL and C-MYC are together up-regulated by
canonical TGFβ signaling and SMAD-dependent target gene expression. Therefore
TGFβ treatment will result in elevated levels of both TIL and C-MYC.

Figure 44. TIL promotes phosphorylation of NF90 at Ser-647. (A) MCF7 cells were
transfected with vector or TIL for 48 hours. NF90 was immunoprecipitated and the
immunoprecipitates were then immunoblotted with AKT-substrate antibody. (B) MCF7
cells were co-transfected with NF90-GFP and either vector or TIL for 48 h.
Immunoprecipitation was performed using anti-GFP and then immunobloted with AKTsubstrate antibody. (C) MDA-MB-231 cells were transfected with si-CTL or si-TIL for 48
hours. Cells were then treated with TGFβ (5 ng/ml) for 30 m. Immunoprecipitation and
Western blot were done as described in panel A.
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The second arm of the pathway we have referred to as the “translational”, named
such since it acts to regulate C-MYC post-transcriptionally. This pathway requires TGFβ
activation of AKT, a known regulator in translational process. We have shown that TIL
binds to NF90, and that this binding is critical for enhancing AKT phosphorylation at
Ser647. This phosphorylation site is the critical event which triggers NF90 translocation
to the cytosol. In the absence of TIL, NF90 phosphorylation and shuttling from nucleus
to cytosol are dramatically inhibited. Enforced expression of TIL can increase p-NF90Ser647 and shuttling NF90 to cytosol. Once in the cytosol, NF90 also binds to AREs of
C-MYC-3’UTR, which promotes C-MYC mRNA stability and increases C-MYC
translation.
A major question remains as to how TIL enhances phosphorylation of NF90. One
explanation is that TIL binds to NF90 first, and this binding results in protein
conformational change to open up Ser647 availability for AKT. Another possibility is that
AKT phosphorylation happens first, and this site is stabilized and protected from
phosphatase activity subsequently by TIL binding. Yet a third possible scenario is that
TIL acts as a molecular scaffold that can also bind to AKT, and serve to direct the
successful interaction between the two proteins. The C-MYC mRNA also serves as a
player in this complex, and similar questions remain as to the order of events of TIL and
C-MYC mRNA binding to NF90. NF90 contains 2 RBDs, so it is possible that TIL and CMYC mRNA binding occurs independently, or lncRNA or mRNA bind first to induce a
protein conformational change to load the second RNA product. The axis by which
TIL/C-MYC/AKT/NF90 work together is a very dynamic process, and one that warrants
future investigation.
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Figure 45. A model proposed by which TIL regulates C-MYC through NF90. TGFβ
can activate target gene transcription through SMAD signaling. TIL and C-MYC are both
transcriptionally activated. TGFβ can also activate the AKT pathway which can influence
translation regulatory machinery in the cell. TIL binding to NF90 enhances AKT
phosphorylation of NF90-Ser647 and C-MYC mRNA shuttling to the cytosol. Once in
the cytosol, NF90 can bind to ARE-containing elements in the 3’UTR of C-MYC to
stabilize transcript and increase protein expression.
Methods

RNA immunoprecipitation (RIP) assay. Briefly, 3ug biotinylated Sense and
Antisense in vitro transcribed TIL was incubated with 1mg HEK293 extract in RIP Buffer,
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respectively. Ribonucleoprotein complexes were immunoprecipitated using Streptavidinagarose (Life Technologies). IPs were washed in RIP Buffer and total isolated protein
was run on SDS-PAGE gel and silver stained. Unique bands were submitted for Mass
Spectrometry protein identification. Previously described in Chapter 4.

Locked nucleic acid in situ hybridization of formalin-fixed, paraffinembedded tissue microarray (LNA-TMA-ISH). TIL LNA probe was end labeled with
digoxigenin-ddUTP terminal transferase. After deparaffinization and antigen retrieval,
hybridizaton with 10 nmol/L LNA TIL probe for 12 hours. After washing sections were
blocked for 1 h and incubated with anti-DIG-AP Fab. Following washing TMAs were
processed and then visualized.

Immunofluorescence,

immunoblotting, and antibodies. As described in

Chapters 3 and 4. Antibodies against total C-MYC was from Santa Cruz
Biotechnologies (Santa Cruz, CA, USA), NF90 from Bethyl Laboratories (Montgomery,
TX USA), phospho-AKT substrate (RXXS/T) from Cell Signaling Technologies (Danvers,
MA USA).

Plasmids and siRNAs. A 656nt cDNA insert of TIL (Exon3) was amplified and
TA-cloned into pGEM-T-easy vector Plasmid containing insert was sequenced, insert
was then isolated by EcoRI restriction digest, and cloned into pcDNA3.1 (pcDNA-TIL).
C-MYC 3-prime UTR cDNA was amplified using Green Taq PCR Master Mix (Promega)
and cloned into pMIR-REPORT luciferase reporter vector (Life Technologies). SiRNAs
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were designed using IDT siRNA Design Software. Two best siRNAs against human TIL
were determined empirically and used for experimentation.

BCSCs sorting by flow for RT-qPCR. HMEC cells were treated with TGFβ (5
ng/ml) for 9 days. Cells were then washed in PBS, trypsinzed, and incubated with
antibodies for CD24-FITC and CD44-PE from BD Biosciences (San Jose, CA USA).
Cells were then sorted by flow cytometry for FITC-positive cells, indicative of
CD24+/CD44- population, and PE-positive cells indicative of CD44+/CD24- population.
Total RNA was isolated from both populations via Trizol and TIL expression was
evaluated by RT-qPCR.

Dual reporter luciferase assay. HEK293 cells were transfected with pMIRLuciferase (firefly) containing constructs and renilla luciferase control plasmid were cotransfected. After 24 hours, pcDNA or TIL was then transfected for 48 hours. At 72
hours time point, cells were lysed, and signal for firefly and renilla luciferase was
measured using Dual-Luciferase Reporter Assay System from Promega. Results are
representative

of

triplicate

ratios
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firefly/renilla

luciferase

signals.

CHAPTER 6:
Conclusions and Implications

Accumulating evidence indicates that the majority of the mouse and human
genomes are transcribed into ncRNAs. Several classes of functional ncRNAs are
emerging within the cell, including lncRNAs. The functional contribution of lncRNAs to
tumorigenesis and cancer progression remains elusive.
The central focus of this dissertation work is to characterize the biological
mechanisms of lncRNAs in the context TGFβ-mediated phenotypes in metastatic breast
cancer, such as EMT and cancer cell stemness. In the initial stages, the primary mouse
mammary cell line NMuMG was treated with TGFβ to induce EMT. Global changes in
lncRNA gene expression were profiled by microarray and significant changes were
validated by RT-qPCR. Our analysis revealed that a total of ~600 lncRNAs were
induced or repressed in this response, respectively. LncRNAs are poorly conserved
across species, however there are examples of well conserved lncRNAs that function in
cancer [33, 48]. Therefore, we developed a strategy to predict mouse lncRNAs that had
a strong potential for a human ortholog.
The motivation behind this strategy was that the end goal was to characterize
important lncRNAs in human cancer. Also, proteins are prime examples of genomic
regions that are very well conserved and contain function gene products. If lncRNAs
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demonstrated similar features, it was likely that this evolutionary selection was due to
the fact that a functional gene product resided in this genomic location. Therefore, our
hypothesis suggested that ortholog lncRNAs are more likely to be functional due to
selective evolutionary pressures.

Strategically, conserved lncRNAs will allow us to

carry out knockout and transgenic animal studies in order to define physiological and
pathological function of these lncRNAs in vivo.
The strategy to predict mouse lncRNAs with a strong potential for a human
ortholog took into account 4 parameters; significant sequence identity and coverage of
transcript, identity mapped to syntenic loci in both genomes, regulated by established
transcriptional factor and pathway (TGFβ), and corresponding transcripts were
intergenic and free standing. Next, we subjected the top 100 mouse lncRNAs induced
by TGFβ in the microarray analysis to these parameters. Ten mouse lncRNAs emerged
as potentially having a human ortholog. Follow-up experimentation showed that 9 were
detected at the RNA level in human (denoting ortholog transcript), 3 were also under
regulation of TGFβ in human, and 1 resided in a genomic location of interest.
This study focused on characterizing 3 of conserved lncRNAs; lncRNA-HIT,
WDFY3-AS2, and TIL. LncRNA-HIT is a 5-prime distal Hoxa residing transcript. It is
becoming well established that Hox gene clusters are lncRNA-governed, and several
important examples have surfaced in literature detailing this regulation [149, 150].
Knockdown experiments using siRNA showed that mouse lncRNA-Hit is functional in
driving TGFβ-induced EMT, migration, and invasion. Overexpression of lncRNA-Hit
disrupted tight junction in NMuMG and this correlated with a drop in E-cadherin
expression. Furthermore, human lncRNA-HIT is significantly elevated in breast cancer,
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and this elevated expression associates with invasive disease, high grade tumor, and
metastatic breast cancer (i.e., lymph node metastasis). LncRNA-HIT positively regulates
HOXA13 mRNA and protein expression in human cell lines. Elevated expression of
lncRNA-HIT could drive high levels HOXA13 in patient tumor to drive oncogenic and
metastatic processes.
WDFY3-AS2 lies in the antisense orientation to protein coding gene WDFY3 on
chromosome 4q21, and also drives TGFβ-mediated phenotypes such as cell motility
and EMT. High levels of WDFY3-AS2 in patients are associated with late stage tumor,
triple-negative subtype, and poorer overall patient survival. Our experimentation has
shown that WDFY3-AS2 positively regulates WDFY3 and STAT3 through protein
binding partner hnRNPR. WDFY3 is a critical regulator of selective macroautophagy by
serving as an adapter for recruitment of the core autophagic machinery. Interestingly, it
has been suggested that several triple-negative breast cancers are driven by STAT3
addicted autophagy. WDFY3-AS2 could be a bridge to link these 2 molecules in TGFβinduced autophagy potentiating a signaling loop that drives cancer phenotypes.
TGFβ-regulated TIL is an 8q23-24 residing lncRNA that also promotes EMT and
cancer cell stemness. In breast cancer patients, elevated levels of TIL associate with
late stage tumor, metastasis, and triple-negative subtype. There have been several
examples of functional lncRNAs in the 8q23-24 region that can regulate C-MYC
expression. Therefore, we examined if TIL also has similar function toward C-MYC. Our
experiments demonstrated that TIL can post-transcriptionally regulate C-MYC through
NF90. Interestingly, TIL enhances phosphorylation of NF90 by AKT resulting in
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increased shuttling of NF90 to the cytosol. In cytosol, NF90 can bind to and stabilize CMYC mRNA and increase C-MYC protein expression.
The 3 candidates mechanistically function very differently from each other
illustrating the dynamic roles of lncRNA can play within a cell. Clearly disruption and
deregulation of lncRNA expression can be important in driving tumorigenesis and
metastatic processes.
The translational impact of lncRNAs is an emerging aspect that has yet to be
extensively explored. In future, there is a great potential for using lncRNA as biomarkers
for diagnostics, monitoring recurrence, and predicting response to therapy. A major
advantage of using RNA as tool and readout is the fact that it can be detected using
PCR based technologies. This means that only a small amount of material is needed to
be informative, and this material can be acquired through non-invasive means like blood
and urine. If a panel of lncRNAs could be identified as specific to a particular cancer,
this could provide a novel avenue to non-invasive preventative screening and diagnosis.
This same principle could be applied to monitoring tumor recurrence and metastasis
after surgery and chemotherapy.
LncRNAs could also serve as important biomarkers in personalized and precision
medicine. For example, it has been reported that triple-negative breast cancers driven
by STAT3-addicted autophagy are responsive to drugs like chloroquine and bafilomycin.
In this case, the status of WDFY3-AS2 expression in the primary tumor would be a
powerful readout for prediction and repurposing these FDA approved drugs. Similarly,
TIL can be a marker of MYC driven malignancy and these patients could be benefit from
newer drugs like JQ-1.
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Of course with the identification of novel oncogenic drivers of cancer, the
question is always asked if these molecules can serve as direct targets for therapy.
There is a major research effort underway to begin targeting the “un-druggable”, which
currently includes the nucleic acids and proteins like transcription factors. This is an
exciting time to expand the therapeutic toolbox, however I do believe directly targeting
lncRNAs in cancer may still take a lot of efforts to prove efficacious. Traditionally,
delivering nucleic acid based therapies, like small antisense oligos (ASOs), has been
difficult due to limitations in methods of delivery and stability of the molecules once
systemically administered. In principle, however, drugs designed against RNAs could be
more specific than those against protein given the exactness of Watson-Crick base
pairing. Future extensive investigation is required for better understanding the basic
underlying biology of lncRNAs and their role in human malignancy such as metastatic
breast cancer with aiming to develop biomarkers and effective novel targeted therapy.
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